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ABSTRACT
PHYSICAL AND BIOLOGICAL PROPERTIES OF COBALT- AND COPPER-DOPED
CALCIUM PHOSPHATES AS BONE SUBSTITUTE MATERIALS
Haley V. Cummings, M.S.
Department of Mechanical Engineering
Northern Illinois University, 2018
Dr. Sahar Vahabzadeh, Director

Arthritis, osteoporosis, and other bone diseases and defects are common medical issues
worldwide. By utilizing ceramic biomaterials as bone substitutes to treat these diseases, bone
regeneration can be promoted and toxicity from the substitute material can be limited. Calcium
phosphate (CaP) ceramics have become popular as bone substitutes due to their biocompatibility
and similarity in composition to natural bone. The purpose of this research was to investigate the
physical properties and biological responses of CaP-based bone substitutes, doped with metal ions.
Some metal ions are present in natural bone in small amounts, and recent studies show they affect
the biological responses of CaPs significantly. Dopants such as magnesium (Mg), strontium (Sr),
silicon (Si) and iron (Fe) alter the phase composition, mechanical properties, osteogenesis and
angiogenesis properties of CaPs, depending on their concentration and method of addition. In the
present study, the effects of cobalt (Co) and copper (Cu) on the physical and biological properties
of two main CaP materials, brushite cement (BrC) and tricalcium phosphate (TCP), have been
investigated. Different concentrations of dopants in forms of oxide and/or chloride were selected
and their effect on phase composition, sintering behavior, density, setting time, compressive
strength and in vitro interaction with osteosarcoma and osteoblast cells were studied. Different

2

techniques of sample preparation, challenges during cement preparation and compact sample
pressing, sintering, and methods of dopant addition are discussed.
The presence of Cu in tricalcium phosphate was found to increase thermal stability of the
material and decrease the impact of sintering temperature on porosity. In addition, Cu caused a
reduction in expression of inflammatory gene markers by human osteoblast cells and an increased
expression at early time points due of osteoinductive markers.
The addition of Cu and Co to brushite cement caused an increase in thermal stability of the
material, and the addition of Cu caused significant increase in setting time. Small dopant amounts
of Co caused decrease in setting time, but higher amounts caused an increase. In addition, Cu
dopant in small amounts resulted in an increase of compressive strength. Both Cu and Co led to a
decrease in expression of inflammatory gene markers by osteoblast and osteosarcoma cells
respectively, and Cu also caused an increase in osteoinductive marker expression. Thus, these
results indicate that Cu and Co have a positive impact on the physical, mechanical and biological
properties of calcium phosphate biomaterials.

i

NORTHERN ILLINOIS UNIVERSITY
DE KALB, ILLINOIS

MAY 2018

PHYSICAL AND BIOLOGICAL PROPERTIES OF COBALT- AND COPPER-DOPED
CALCIUM PHOSPHATES AS BONE SUBSTITUTE MATERIALS

BY
HALEY V. CUMMINGS
©2018 Haley V. Cummings

A THESIS SUBMITTED TO THE GRADUATE SCHOOL
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS
FOR THE DEGREE
MASTER OF SCIENCE

DEPARTMENT OF MECHANICAL ENGINEERING

Thesis Director:
Sahar Vahabzadeh

ii

ACKNOWLEDGMENTS

I want to thank Mr. Gregg Westberg of the Microelectronics Research Development
Laboratory (MRDL), Dr. Michael Haji-Sheikh of the Northern Illinois University Department of
Electrical Engineering, Michael Reynolds and Dave Garcia of the Northern Illinois University
Machine Shop, and Stanislaw Kolesnik of Northern Illinois University Department of Physics for
their assistance and support through my research. I would also like to thank Benyamin Salehi,
Sarah Fleck and Kareem Elkwae for working all hours of the night and day to make samples with
me. Thanks to Weiguo Han for teaching this mechanical engineer how to work with cells. To my
committee, Dr. Federico Sciammarella and Dr. Sherine Elsawa, thank you for your input, support
and patience with me through this research and writing process. Finally, thank you to my advisor,
Dr. Sahar Vahabzadeh for introducing me to your passion in this field of biomaterials and for your
recommendations and encouragement through the experimentation and writing of this thesis.

iii

DEDICATION

This work is dedicated to my parents, Mike and Melissa, and my brother and sister, Ryan and
Lauren, who have shaped me, pushed me, challenged me and loved me since day one
To my friends, who keep me sane in the insane times, and who ask the tough questions
And to the unexplainable, unattainable God of the universe, in whom science and faith meet, and
in the pursuit of whom I find purpose

iv

TABLE OF CONTENTS

Page
LIST OF TABLES ........................................................................................................................ vii
LIST OF FIGURES ..................................................................................................................... viii

Chapter
CHAPTER 1

Page
INTRODUCTION ................................................................................................. 1

1.1 Biology of Bone ...................................................................................................................1
1.2 Effective Markers in Bone Remodeling ..............................................................................6
1.3 Need for Bone Substitute Materials .....................................................................................9
1.4 Calcium Phosphate Bone Substitutes ................................................................................14
1.5 Osteoinductivity of Biomaterials .......................................................................................16
1.6 Trace Elements Used to Enhance Osteoinductivity ...........................................................18
1.7 Fabrication of Bone Substitute Materials ..........................................................................19
1.8 Research Objectives ...........................................................................................................21
CHAPTER 2

COPPER-DOPED TCP ....................................................................................... 24

2.1 Introduction........................................................................................................................24
2.2 Materials and Methods ......................................................................................................26
2.2.1 Sample Preparation ..................................................................................................26
2.2.2 Phase Composition, Surface Morphology and Density ...........................................28
2.2.3 Cell Culture ..............................................................................................................29
2.2.4 Assessment of Cell Growth Using XTT Assay .......................................................30
2.2.5 Assessment of Gene Expression ..............................................................................31
2.2.6 Statistical Analysis...................................................................................................32
2.3 Results................................................................................................................................33
2.3.1 Phase Analysis .........................................................................................................33

v
Page
2.3.2 Density .....................................................................................................................35
2.3.3 Assessment of Cell Proliferation .............................................................................37
2.3.4 Assessment of Cell Differentiation and Inflammation ............................................38
2.4 Discussion ..........................................................................................................................40
2.5 Conclusion .........................................................................................................................45
CHAPTER 3

COPPER- AND COBALT-DOPED BRC .......................................................... 46

3.1 Introduction........................................................................................................................46
3.2 Materials and Methods ......................................................................................................49
3.2.1 Powder Preparation ..................................................................................................49
3.2.2 Cement Preparation .................................................................................................51
3.2.3 Phase Composition and Surface Morphology .........................................................51
3.2.4 Setting Time.............................................................................................................52
3.2.5 Compressive Strength ..............................................................................................52
3.2.6 Cell Culture ..............................................................................................................53
3.2.7 Assessment of Cell Growth Using XTT Assay .......................................................54
3.2.8 Assessment of Gene Expression ..............................................................................54
3.2.9 Statistical Analysis...................................................................................................57
3.3 Results................................................................................................................................57
3.3.1 Phase Analysis .........................................................................................................57
3.3.2 Surface Morphology ................................................................................................61
3.3.3 Setting Time.............................................................................................................64
3.3.4 Compressive Strength ..............................................................................................67
3.3.5 XTT Assay ...............................................................................................................68
3.3.6 Gene Expression ......................................................................................................69
3.4 Discussion ..........................................................................................................................71
3.4.1 Cu-BrC Discussion ...................................................................................................73
3.4.2 Co-BrC Discussion .................................................................................................739
3.5 Conclusion .........................................................................................................................82
CHAPTER 4

SUMMARY AND FUTURE WORK ................................................................. 84

4.1 Summary ............................................................................................................................84

vi
Page
4.2 Future Work .......................................................................................................................86
REFERENCES ............................................................................................................................. 88

vii

LIST OF TABLES
Page
Table 1: Properties of Cancellous Bone [9] .................................................................................... 2
Table 2: Properties of Human Bone [10] ........................................................................................ 3
Table 3: Composition of Bone Relative to Mineral Fraction or Wet Human Bone (Co and Cu)
[67,68] ........................................................................................................................................... 14
15
Table 4: Calcium Phosphate Biomaterials [66] ............................................................................ 15
Table 5: α-TCP Phase Intensity Percentages ................................................................................ 33
Table 6: Comparison of Open and Total Porosities at Different Sintering Temperatures............ 35
Table 7: Copper DCPD and ß-TCP Phase Intensity ..................................................................... 58

viii

LIST OF FIGURES
Figure 1: Cortical Bone vs. Cancellous Bone [7] ........................................................................... 2
Figure 2: Constant Bone Remodeling Process Facilitated by Osteoclasts and Osteoblasts [18] ... 4
Figure 3: RANKL Binding Mechanism [21] .................................................................................. 5
Figure 4: : Imbalance of Osteoclast and Osteoblast Activity Leads to Osteoporosis [60] ........... 10
Figure 5: Types of Grafts .............................................................................................................. 11
Figure 6: Fibrous Encapsulation vs. Stable Fixation [63]............................................................. 12
Figure 7: Cu-Doped TCP Samples on Scaffolds for Sintering ..................................................... 27
Figure 8: Osteoblast Cells Used for Cell Culture ......................................................................... 29
Figure 9: Epoch Plate Reader for XTT ......................................................................................... 30
Figure 10: XRD of TCP Powder and Samples Sintered at 1050, 1150 and 1250 °C ................... 34
Figure 11: Total and Open Porosity of TCP Samples Sintered at 1050 and 1150 °C .................. 36
Figure 12: Proliferation of Osteoblast Cells After 1 and 5 Days Incubation ................................ 37
Figure 13: Gene Marker Expression of Osteoblast Cells After 1 and 5 Days Incubation ............ 39
Figure 14: Cu Deposition on Furnace Heating Elements ............................................................. 41
Figure 15: Doped TCP Powders in Crucibles After Calcination .................................................. 50
Figure 16: Sterile Cell Culture Hood Located in Department of Biology .................................... 53
Figure 17: Brushite Cement Samples for qPCR ........................................................................... 56
Figure 18: Copper DCPD and ß-TCP Phase Intensity .................................................................. 59
Figure 19: Copper TCP and BrC XRD Graphs ............................................................................ 60

ix
Figure 20: Cobalt TCP and BrC XRD Graphs.............................................................................. 62
Figure 21: Cobalt BrC SEM Images ............................................................................................. 63
Figure 22: Copper BrC Initial and Final Setting Times ................................................................ 65
Figure 23: Cobalt BrC Initial and Final Setting Times ................................................................. 66
Figure 24: Copper BrC Compressive Strength ............................................................................. 67
Figure 25: Relative Osteoblast and MG-63 Osteosarcoma Cell Proliferation .............................. 68
Figure 26: Gene Marker Expression of Osteoblast Cells After 1, 3 and 7 Days Incubation ........ 70
Figure 27: HIF-1α and GLI2 Expression Under Hypoxia and Normoxia .................................... 72
Figure 28: CoCl2 Leached Out of Samples ................................................................................... 80

1

CHAPTER 1 INTRODUCTION

1.1

Biology of Bone

A healthy adult’s dry bone mass comprises 15-20% of one’s total body weight while the
skeletal system overall is 30-40% of an adult’s weight [1]. This system is integral in structurally
supporting the body and protecting the vital organs, and it also enables motion through connection
with the muscles. What is often referred to as “bone” is more formally known as osseous tissue.
The two types of bone tissue present in the body and depicted in Figure 1 [2] are cancellous and
cortical, which are mainly identified by their densities: cortical bone is much denser than
cancellous bone, which is porous, flexible, and much weaker than cortical. At the microstructure
level, cortical bone functions through the Haversian, or osteon, system. In this system, the blood
flow is conducted through “Haversian canals,” which are in the middle of each osteon and
surrounded by a cylindrical lamellae tissue layer made from collagen fibers [2]. These single
Haversian systems are reported to have tensile strengths of around 17 ksi, compressive strengths
around 16 ksi, bending strength around 56 ksi and torsional strength around 29 ksi [3–6]. In
contrast, cancellous bone (see Table 1) is composed of trabecula, which is bone tissue formed into
a rod to enhance mechanical functionality. This structure allows cancellous bone to have a higher
degree of porosity, mostly greater than 75%, while still maintaining a reasonable strength,
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Figure 1: Cortical Bone vs. Cancellous Bone [7]

Table 1: Properties of Cancellous Bone [8]

Mechanical Property

n

Age

Apparent Density (lb/in3)

Young's Modulus (Mpa)

142

67±15

0.00978

Shear Modulus (Mpa)

42

Bovine

-

σy (MPa, tension)

52

65±14

0.01048

σy (MPa, compression)

68

65±14

0.00978±0.00614

σult (MPa, tension)

22

54±11

0.00686±0.00145

σult (MPa, compression)

22

54±11

0.00614±0.00145
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depending of course on the age of the bone and region in the body [8,9].
Cortical bone is often found as the outside tissue surrounding the inner cancellous bone,
though cancellous bone is also found on the end of longer bones such as the femur. Mechanical
properties of the femur, tibia and other bones can be seen in Table 2. Cancellous bone is remodeled
more often than cortical bone, which is a function of its higher metabolic activity compared to
cortical bone and also means that it is often younger than cortical bone [2]. This remodeling
process involves the resorption of old bone tissue and the formation of new bone tissue and occurs
mainly as a function of the bone cells. Osteoblasts are the bone forming cells but are also involved
in resorption, while osteoclasts only perform the resorption. When osteoblasts form new bone, it
is initially uncalcified and known as osteoid bone.

Table 2: Properties of Human Bone [10]

Human (20-39 years) Bone

Femur

Tibia

Humerus Radius

Ultimate Tensile Strength (Mpa)

124±1.1

174±1.2 125±0.8

152±1.4

Ultimate Percent Elongation

1.41

1.50

1.43

1.50

Modulus of Elasticity in Tension (Gpa)

17.60

18.40

17.50

18.90

Ultimate Compressive Strength (Mpa)

107±4.3

Ultimate Percentage Contraction

1.85±0.84

Ultimate Shear Strength (Mpa)

54±0.6

Torsional Modulus of Elasticity (Gpa)

3.20
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Osteoblasts originate from mesenchymal stem cells (MSC), which are multipotent cells
that have the potential to differentiate into osteoblasts, adipocytes, chondrocytes and myoblasts
[11]. MSCs which differentiate to osteoblasts react to the runt-related transcription factor 2
(RUNX2) protein, and osteoblast differentiation, in turn, is regulated by various hormones as
pictured in Figure 2 [12,13]. Osteoblasts differentiate into bone lining cells known as osteocytes
[14]. These osteocytes embed themselves in the bone matrix newly formed by osteoblasts and also
may play a role in mechanical stress transduction and thus gene regulation, though this process is
not yet well understood [15–17]. The continued differentiation of osteoblasts relies on osteoblastproduced cytokines like insulin growth factor 1 (IGF-1) and bone morphogenetic proteins (BMPs)
[11]. Collagen, which makes up a significant portion of the organic portion of the bone matrix, is
produced by osteoblasts, as are noncollagenous proteins like osteocalcin and osteonectin [11].

Figure 2: Constant Bone Remodeling Process Facilitated by Osteoclasts and Osteoblasts [18]
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Another significant protein secreted by osteoblasts is osteoprotegerin (OPG), which is a
decoy receptor for receptor activator of nuclear factor kappa-ß ligand (RANKL). This is significant
because differentiation of osteoclasts relies on RANKL binding with receptor activator of nuclear
factor κ ß (RANK) [19,20]. Thus, as OPG binds with RANKL instead, osteoclast differentiation
is inhibited (Figure 3).

Figure 3: RANKL Binding Mechanism [21]

Compared to osteoblasts, osteoclasts are large, multinucleated cells whose main purpose is
the resorption of bone. To resorb bone, osteoclasts attach to the bone surface and create a seal
around the area to be resorbed. They then secrete hydrochloric acid, which dissolves the mineral,
and the proteolytic enzyme cathepsin K, which breaks down the bone matrix [19,22]. As
mentioned previously, the differentiation of osteoclasts is significantly regulated by the prevalence
of OPG, RANKL and RANK, where an overabundance of OPG can cause the resorption process
to decrease, leading to increased bone mass and thus osteopetrosis, and conversely a lack of OPG
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can lead to excessive bone resorption and osteoporosis [23]. However, there are many other
markers that indicate healthy bone formation, including alkaline phosphatase 1 (ALP-1), vascular
endothelial growth factor (VEGF), interleukin-6 (IL-6), interleukin-17 (IL-17), tumor necrosis
factor-α (TNF-α), collagen type 1 α (COLA-1), osteocalcin (OCN) and hypoxia inducible factor
1-α (HIF-1α).

1.2

Effective Markers in Bone Remodeling

OPG and RANKL – As previously discussed, OPG is a decoy receptor for RANKL secreted by
osteoblasts. It has been observed that with an upregulation of RANKL, OPG is downregulated and
osteoporosis results [19]. However, when OPG is able to bind with RANKL, osteoclostogenesis
is inhibited [24]. Studies have shown that OPG-deficient mice experience osteoporosis and loss of
bone mass while OPG-transgenic mice experience osteopetrosis [25]. Interestingly, OPG has also
been observed to inhibit calcification of large blood vessels [19]. RANKL is a member of the
tumor necrosis factor (TNF) family, and its expression is affected by T cell activation [24]. It plays
a major role in the formation and activation of osteoclast cells and also appears to play a role in
the rheumatoid arthritis joint breakdown [19].
ALP – ALP is an osteoblast-synthesized ectoenzyme that plays a role in bone calcification [26–
28]. Its exact role is not fully understood, but it is clearly linked to healthy bone. An increased
expression of ALP is observed with osteoblast differentiation, and many studies suggest that early
indication of cellular activity and differentiation can be gathered from the measured ALP
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expression [29]. In addition, mechanical force has been observed to increase ALP expression, and
ALP expression is increased during fracture healing [28]
VEGF – This growth factor is expressed by osteoblasts, osteoclasts, and chondrocytes and
stimulates and regulates their growth, differentiation, proliferation and survival [30–32]. It also
plays a large role in angiogenesis, or the growth of blood vessels, as well as in the ossification of
bone [33,34]. Osteogenesis and angiogenesis are closely related and interdependent, and VEGF is
one growth factor that bridges the gap between the two. VEGF is integral in endochondral
ossification, which is one method by which bone is ossified [30]. VEGF has been found to
stimulate osteoblast differentiation by as much as 70%, though low expression is observed at the
beginning of osteoblast differentiation, and most expression of VEGF occurs during mineralization
[35,36]. Several studies have shown that scaffolds incorporated with VEGF and slow-release
mechanisms are therapeutic for bone healing [30,37]. However, excessive amounts of VEGF can
also decrease bone healing [31]].
IL-6 – The presence of the proinflammatory cytokine IL-6 can stimulate bone formation by
inducing osteoblast differentiation and can also inhibit the formation of osteoclasts [38,39]. They
also enhance the formation of the extracellular matrix (ECM) and increase expression of ALP<
OCN and other genes which are involved in calcification [39,40]. An increased presence of IL-6
has been found in the joints of patients with osteoarthritis, and inhibited expression of IL-6 has
been found to eliminate osteoarthritis in mice studies [38,41]. In addition, osteoblasts have seen
protection from apoptosis due to TNF-α serum depletion by IL-6, though results are inconclusive
[39].
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IL-17 – The IL-17 cytokine is proinflammatory and mostly originates from specialized T cells
[42,43]. It is associated with inflammatory diseases like rheumatoid arthritis and is profuse in the
sunovial fluid of such patients’ joints. Studies have shown IL-17 to stimulate ALP expression in
MSCs and to have a positive effect on calcium and mineralized deposition of the ECM [44].
Reports also show that IL-17 promotes osteogenesis and osteoclastogenesis, though its role is still
being defined [43,44]. IL-17 may have a stimulating effect on RANKL expression and also may
promote osteogenic differentiation of MSCs [43,45].
TNF-α – The TNF-α cytokine is mainly secreted by macrophages and leads to the formation and
activation of osteoclasts [46]. It is also linked to reduced osteoblast proliferation, and it has been
found to limit the expression of differentiation markers of osteoblasts like OCN, COLA-1 and
ALP. As such, TNF-α is associated with bone loss and excessive bone resorption and is associated
with inflammatory bone diseases [46]. In rat calvaria models, addition of TNF-α decreased the
osteoblast proliferation to maturity and decreased osteoblast differentiation [47].
COLA-1 – Collagen is abundantly produced by osteoblast cells, and COLA-1 is a gene that
produces part of type 1 collagen, which is completed by the chain produced by COLA-2. Type 1
collagen is fibril forming and is essential to the production of the ECM [48]. In addition, the
COLA-1 gene has been linked to ALP production and the differentiation of osteoblast cells [48].
OCN – Osteocalcin is secreted almost entirely by osteoblast cells and is one of the most prolific
noncollagenous proteins found in bone [49,50]. Secretion of this protein is found mostly in mature
osteoblast cells, and it acts to recruit osteoclasts and osteoblasts [51]. It also plays a role in
signaling and is considered an indicator of bone formation [49–51]. OCN’s ability to bind with
hydroxyapatite makes it an integral part in the mineralization of bone and the ECM, though some
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studies suggest that OCN does not play a role in the mineralization of bone [50–52]. OCN is also
an indicator of bone metabolic activity [49].
HIF-1α – In general, the activation of hypoxia inducible factors (HIFs) occurs in response to a
reduction in oxygen, as the name suggests. HIF-1α specifically encodes the α subunit of HIF-1 and
activates the transcription of genes such as VEGF. As such, HIF-1α is a crucial link between
angiogenesis and osteogenesis in skeletal and bone formation [53,54]. In addition, studies show
that a lack of HIF-1α results in bones with smaller diameter and a lack of vascularization, and they
show that it contributes to the protection of articular cartilage in certain cases [53,55].

1.3

Need for Bone Substitute Materials

Osteoporosis, arthritis, bone fracture and other bone trauma are prevalent around the world
and cause significant loss of productivity and decrease in quality of life. According to a 2017
Centers for Disease Control study, the 10-year probability of a hip fracture within the next 10 years
for an individual aged 80 or older in the United States is 72% [56]. This fracture becomes more
likely with osteoporosis because, as seen in Figure 4, the density of bone decreases. In addition, it
is estimated that 16% of Americans suffer from arthritis, and 43% of those experience physical
limitations due to the disease [57]. In 2013, arthritis cost $304 billion in wages lost and medical
expenses incurred [58]. In addition, astronauts exposed to prolonged zero-gravity effects
experience greater risk for osteoporosis and bone loss, especially in the spine or hip [59].
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Figure 4: : Imbalance of Osteoclast and Osteoblast Activity Leads to Osteoporosis [60]

Established methods such as grafts (Figure 5) have been implemented in the medical
community to alleviate the effects of bone loss. Autografts, which are tissue grafts from one place
on a patient’s body to another, are by far the desired remedy, but this solution requires two
surgeries and additional time under anesthesia for the afflicted individual, which increases the
potential for additional damage. Allografts are tissue grafts from a donor to a patient and are
another viable solution, but the patient is subject to rejection of the donated tissue by the body. An
allograft from a genetically identical donor is known as a synograft and is usually not rejected by
the patient’s body, but this method of transplant still requires two surgeries. Transplanting tissue
from a different species, known as a xenograft, is also utilized in the medical industry, but as with
allografts there is a potential for the body to reject the unknown tissue.
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Figure 5: Types of Grafts

As an alternative solution, much emphasis has been placed on biomaterials. In a general
sense, a biomaterial is any synthetic or natural material that is used in the body, which can
include metals, ceramics, polymers and any combination of these.
.

Heat-activated polymers are particularly intriguing as drug delivery systems and stents. For

load-bearing bone sections or joint replacement, metal biomaterials are a natural choice, as they
are strong and resistant to fatigue. However, metals are often toxic to the body and, as they remain
in the body over time, tend to leach harmful ions into the body. This can cause significant health
concerns, as observed with metal-on-metal hip prostheses that require a second surgery to remedy
the issues [61]. In addition, these materials do not integrate with the surrounding bone, which can
cause a phenomenon known as fibrous encapsulation (Figure 6), which occurs when the implant
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is surrounded by tissue but not integrated into the body [62]. This can cause the implant to loosen
and eventually can necessitate a second surgery to repair the affected area. To counter this, the
metal can be coated with a ceramic material. Ceramics have a composition like that of bone, which
allows the body to more readily accept the implant and integrate it into the body. In addition, the
coating can reduce the toxicity of the implant since the friction between the implant and the
surrounding bone is eliminated.

Figure 6: Fibrous Encapsulation vs. Stable Fixation [63]

However, in small bone defect sites in non-load bearing areas, ceramics are often viewed
as superior to metals. While these materials lack tensile and fracture strength, they have excellent
compressive strength and as previously mentioned, have similar composition to natural bone.
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There are numerous varieties of ceramics available and effective as implants, including bioglasses,
metal oxides and calcium phosphates.
Bioceramics are advantageous for use in biomaterial applications because they are often not
toxic to the body. Some bioceramics, when implanted, can bond with the surrounding tissue and
thus have superior fixation compared to metals or other inert ceramics. Some ceramics are inert
and experience fibrous encapsulation, but this can be avoided if the materials is porous. The
porosity of many ceramics can be manipulated and optimized to ensure adequate pore size and
distribution. Both macroporosity (>100 μm) and microporosity (<100 μm) are desired in
biomaterials for biodegradability, fixation, and enhanced osteoconduction [64]. If a material has
surface reactivity with the surrounding tissue, it will biologically fixate to the tissue and avoid
detrimental fibrous encapsulation. Porosity plays a large role in accomplishing this and is
necessary for the circulation of blood and new cells while also providing a mechanism for waste
removal. Growth factors, BMPs and other osteogenic factors also circulate through these
interconnected pores and ultimately lead to enhanced osteoinduction. Mechanical strength is also
regulated through pore size and interconnectedness. Thus, CaP biomaterial porosity is an integral
consideration in designing scaffolds and implants.
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1.4

Calcium Phosphate Bone Substitutes

Calcium phosphate ceramics are well-suited for bone substitution applications, as their
composition is similar to that of human bone. Bone is composed of 36 wt. % calcium and 17 wt.
% phosphorous (Table 3) which allows the body to more readily accept these ceramic bone
substitutes compared to other materials which the body is unfamiliar with and thus rejects [65]. In
addition, due to the similarity of the material to bone, CaPs often elicits a biological response from
the body and bonds are formed between the implant and the native bone tissue. This leads to greater
integration and higher success levels of implants. CaPs are also resorbable, which means the
implant dissolves as the bone tissue regenerates. The physiological reactions of the many types of
calcium phosphates are distinguishable by their calcium to phosphate ratio, which can be used to
determine the solubility product and thus the application of the material, as well as by their phase
composition and crystallinity. CaPs with a small solubility product such as hydroxyapatite (HA)
have a high Ca/P ratio and are useful for more permanent applications, as the substitute will
dissolve slowly over many years [66]. In contrast, materials with high solubility products and low
Ca/P ratios, such as monocalcium phosphate monohydrate (MCPM), dissolve quickly and are
useful in short-term applications [66]. Of specific interest in this research are tricalcium phosphate
(TCP) and dicalcium phosphate dihydrate (DCPD), which is also known as brushite. TCP can be
expressed in two different phases (Table 4) based on the temperature at which it is calcined: αTCP, which forms at temperatures above 1250 °ß-TCP, which forms at lower temperatures and is
stable up to 1125 °C [67]. α-TCP has a solubility factor of 10-26 while ß-TCP has a solubility factor
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stable up to 1125 °C [67]. α-TCP has a solubility factor of 10-26 while ß-TCP has a
Table 3: Composition of Bone Relative to Mineral Fraction or Wet Human Bone (Cobalt and Copper) [69,70]

Wt.%
Ca
P
CO2
Na
K
Mg
Sr
Cl
F

Bone (%)
36.6
17.1
4.8
1
0.07
0.6
0.05
0.1
0.1

Table 3: Calcium Phosphate Biomaterials [66]

Chemical
Calcium Phosphate

Abbreviation Formula

Monocalcium phosphate monohydrate MCPM
Dicalcium

phosphate

Ca/P Molar Solubility
Ratio

Product

CaH4P2O8

0.5

7.2 x 10-2

dihydrate

(Brushite)

DCPD

CaHPO4 2H2O

1

2.5 x 10-7

α-Tricalcium phosphate

α-TCP

α-Ca3(PO4)2

1.5

3.16 x 10-26

β-tricalcium phosphate

β-TCP

β-Ca3(PO4)2

1.5

1.25 x 10-9

Hydroxyapatite

HA

Ca5(PO4)3(OH)

1.67

1 x 10-38
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of 10-29, though both phases have a Ca/P ratio of 1.5 [66]. This difference in solubility products by
a factor of 3 is significant and is a good example of how minor variations in Ca/P ratio can affect
the solubility product. The Ca/P ratio of DCPD is 1.0, and it has a solubility factor of 10-7, which
indicates a much higher rate of resorbability compared to TCP [66]. DCPD is often used as a
cement due to its high solubility product. However, as ceramics, these materials have low tensile
and fracture strengths, which makes them unsuitable substitutes in load bearing areas, though they
can be used in small defects that bear relatively small loads [68]. In addition, as the implants are
resorbed, their mechanical strength will decrease because of the dissolution of the material.

1.5

Osteoinductivity of Biomaterials

To quantify the performance of these bone substitute materials, the osteoconductivity and
osteoinductivity of the materials are observed, among other properties. Osteoconductivity, which
is the ability of a material to act as a scaffold for new bone growth, is an inherent property of all
CaPs. Osteoinductivity, which is the ability of a material to induce new bone formation without
growth factors, is a property that CaPs without additives do not possess. In specific instances, some
CaPs have exhibited osteoinductive properties, but the enhancement of the osteoinductive
properties of CaPs remains a crucial topic in bone engineering [71]. Osteoinduction is vital because
these CaP bone substitutes should contribute to the ultimate healing of the defect site. As was
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previously mentioned, as the substitutes are resorbed, new bone formation should occur so that the
defect site can return to complete functionality.
Several methods for enhancing osteoinduction have been studied and reported, including
using CaPs enhanced with trace amounts of metal ions or growth factors [68,72–74]. The use of
growth factors to enhance osteoinductivity has been well documented and many instances of
studies performed using bone morphogenetic proteins (BMPs), insulin-like growth factors (IGFs),
MSCs, vascular endothelial growth factors (VEGFs) and others can be found [75–78]. These
growth factors enhance cell proliferation and the expression of many proteins and indicators of
bone growth such as collagen and osteocalcin. Likewise, there is a wealth of research and
publications that have been produced regarding incorporation of metal ions into CaPs to enhance
osteoinductivity. Trace elements are found in small amounts within the body already, and they
play vital roles in maintaining health. Iron’s presence in the blood, magnesium’s presence in tissue
and zinc’s cellular presence are just a few examples of this. By incorporating trace amounts of
metal in CaP bone substitutes, the therapeutic effects of these metals can be harnessed. Of course,
an excess of metal is toxic at the cellular level, and as such, in-depth studies must be conducted.
Among the elements that have been studied are Mg, Li, Fe, Si, Sr, Cu, Co, Zn, and many others.
Depending on the amount of trace element used, the type of CaP, the type of cell or implant
location studied and other factors, the biological response varies. Zn and Sr are often utilized or
combined in cellular studies. They have been found to increase ALP expression and cell adherence
in osteoblast cells cultured on doped BrC samples, as well as in pig trabecular bone [79]. Other
studies have corroborated the positive effects of doping calcium phosphates with Zn and Sr on
bone formation and healing [76,80]. Mg has also been linked to OPG and RANKL levels and bone
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morphogenic protein 2 (BMP-2) expression [81–83]. Cell differentiation and proliferation have
been enhanced with the incorporation of Li as a dopant in CaP materials, as has the ability of the
cell structure to mature [84–86]. Si promotes expression of VEGF and ALP and also enhances
matrix mineralization through collagen production [87–90]. In the current research, Cu and Co
specifically were studied and were observed as dopants in both ß-TCP and BrC in various dopant
amounts.

1.6

Trace Elements Used to Enhance Osteoinductivity

Instances of both cupric (Cu2+) and cuprous (Cu+) copper can be found in the body, and most
copper intake comes from digested food, while about 10% comes from water [91]. A normal adult
has between 18-45 µg of Cu per gram of dry weight located within the liver, and has about 6 mg
of Cu in the blood [92]. Copper plays a strong role in Fe metabolism and is itself metabolized in
the liver and absorbed mostly in the small intestine, where it is bound to albumin and transported
in blood [91,93]. For the average adult, a lethal dose of Cu is between 10-20 grams, while general
Cu toxicity can lead to liver cirrhosis. In cellular toxicity, the most popular theory states that cell
death occurs due to the free ions of Cu forming reactive oxygen species (ROS) [91]. Regarding
cellular presence, Cu has been linked to angiogenesis, or the growth of blood vessels, and to the
expression of VEGF, which is a vital growth factor that is expressed during angiogenesis [94–96].
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Cobalt is another essential element that is well known in the composition of vitamin B12.
The highest concentrations of Co are found in the liver and kidney, while it is absorbed from the
gastrointestinal and pulmonary tracts [97]. The average adult has an intake between 5-45 µg of Co
per day and has about 1.5 mg of Co stored in the body [97,98]. It has been reported that the main
source of Co toxicity comes from essential macromolecules mistakenly binding to Co instead of
the correct element. This causes the macromolecule to function improperly and is most common
for macromolecules seeking Fe due to the similar radius of Fe and Co [99]. In clinical settings, the
administration of Co was used for treatment of anemia in the 1940s, where 18.5-37 mg Co per day
was prescribed to patients. These patients did not show any significant signs of toxicity, but
children given 3-4 mg of cobalt chloride per kg of body weight experienced goitrogenic effects
until the dose was discontinued [98]. In addition, cardiomyopathy outbreaks were reported from
those who ingested Co-infused beer, and neurological symptoms were experienced due to Co
toxicity from metal-on-metal hip prostheses [97,100,101].

1.7

Fabrication of Bone Substitute Materials

Fabrication methods of CaP bone substitute materials are diverse and depend extensively on
their application and the desired properties. 3D printing of bioceramics offers the fabricator the
ability to design scaffolds with specific pore size and overall shapeand allows quick reproduction.
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In addition, growth factors and proteins can easily be incorporated into the scaffold. To incorporate
these biological factors, however, low-temperature printing is needed, which poses a challenge
[102]. The integration of polymers into the scaffold to enhance the mechanical properties and
reduce material impurities has also been utilized in the form of particle leaching, thermally induced
phase separation, electrospun scaffolds, and others [103,104]. The aforementioned methods allow
for customizable pore size and enhanced interconnectivity of the materials. Other applications
require injectability, for which cements are particularly well suited. Cements are created by mixing
a solid and a liquid, after which their shape can be molded before the setting reaction completes
and the cement is hardened. In addition, these cements inherently have microporosity, which
enhances biointegration [105]. Early issues observed with the use of cements were poor binding
properties, so additives such as polyethylene glycol (PEG) were necessary to eliminate such
problems [106,107]. To fabricate, the powder and liquid are mixed, poured into a mold, and
allowed to set at high humidity. Other methods of powder preparation include uniaxial and isostatic
pressing followed by sintering at high temperatures [108].
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1.8

Research Objectives

Based on the literature review and previous research conducted, new areas of research were
defined. The prevalence of CaPs used as biomaterials is evident, but much research and discovery
are yet to be done before these ceramics can reach their potential for impacting the medical
community.
The biocompatibility, resorbability, mechanical properties, physical properties and
manufacturability exhibited by tricalcium phosphate and dicalcium phosphate dihydrate
contributed to the decision to utilize these as the two materials investigated herein. Significant
previous research has been done regarding these materials, and this research has served to extend
the knowledge base available regarding them.
Cu has been identified as an essential trace element in living tissue, and previous studies
have shown its effectiveness in stimulating angiogenesis and cell proliferation. The research lacks
details regarding the effect of Cu on specific markers of osteoinductive genes, and lacks coverage
of Cu additives in brushite cement and tricalcium phosphate samples.
Likewise, the anti-inflammatory effects of Co additives to bioceramics have been
documented, but Co as an additive to brushite as a scaffold for cell growth is relatively absent in
literature, as are studies discussing the role of Co in cell proliferation.
Thus, the research objectives of this study are:
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Quantify physical, mechanical and biological effects of doping tricalcium phosphate with Cu
Tricalcium phosphate powder was synthesized by the solid-state method, and relative
amounts of Cu were added prior to calcination at 1050 °C. The resulting powder was mixed with
ethanol and ball-milled to break up the material into fine powder, then dried in a furnace. Fine
powder was formed into cylinder scaffolds by a die and uniaxial press and subsequently sintered.
The crystal structure of the samples was studied by x-ray diffraction (XRD), and the surface
morphology was observed by scanning electron microscopy (SEM). The density was tested by
measuring volume, dry and wet weight of samples and utilizing Archimede’s method of
calculation. For biological studies, the samples were sterilized and then seeded with osteoblast
cells, which were harvested at various time points. Quantitative real-time polymerase chain
reaction (qPCR) methods were used to quantify gene expression, and XTT assay was used to obtain
cellular proliferation.
Quantify physical, mechanical and biological effects of doping brushite cement with Cu and
Co
Brushite powder was obtained by first synthesizing tricalcium phosphate powder and
calcinating at 1050 °C. To obtain fine powder, the calcinated material was mixed with ethanol,
ball-milled and dried in a furnace. Half of the powder was kept coarse, and a mixture of fine TCP,
coarse TCP, monocalcium phosphate monohydrate (MCPM), magnesium hydrogen phosphate
trihydrate, sodium pyrophosphate dibasic and magnesium sulphate was ground with a mortar and
pestle to mix evenly. XRD was used to quantify crystal structure, and SEM illuminated the surface
morphology. Compression testing was conducted to obtain the compression strength and a Gilmore
needle was used to test setting time. The brushite powder was mixed with a polyethylene glycol

23
(PEG)-water combination to form cement and then was poured into a mold. Samples were allowed
to set at 100% humidity for one hour, then submerged in phosphate-buffered saline (PBS) for 24
hours to complete setting reaction. Sterilized samples were seeded with osteoblast cells, and qPCR
and XTT assay were used to obtain gene expression and cell proliferation.
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CHAPTER 2 COPPER-DOPED TCP

2.1

Introduction

While all CaPs are osteoconductive, many of them including β-TCP lack osteoinductivity
[73]. Osteoinduction in CaPs including ß-TCP is often enhanced by incorporating growth factors
and dopants [68,72,73]. The effects of bone morphogenic protein 2 (BMP-2) addition to gelatinous
ß-TCP scaffolds were studied in vivo in the back subcutis of rats, and it was found that with
increased percentage of (BMP-2) incorporation into the scaffolds, increased alkaline phosphatase
(ALP) and osteocalcin (OCN) activity were observed, and thus osteoinductivity was enhanced
[75]. We also found that the phase intensity of ß-TCP increased with increasing Co [109]. In
another study, β-TCP doped with MgO, SrO and SiO2 was substituted into distal femur cortical
defect in rats and histomorphology of the defects was performed 4, 8, 12 and 16 weeks postimplantation [110]. The physical properties of the samples were affected by the dopants, as the
XRD results showed the β-to-α transition temperature increased as a result of MgO addition.
Further, β-TCP doped with a combination of MgO and SrO was found to enhance bone formation
and remodeling through high osseous activity [110]. We previously showed that osteoblast cells
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cultured in the presence of Li-doped β-TCP had increased cell adhesion and proliferation compared
to pure TCP samples [84]. The stability of the Li-doped samples was also increased, as was the
bulk density of the samples due to the decrease of lattice volume by substitution of Li ions into the
Ca sites [84].
Cu has been widely used in biomedical applications and is necessary for many physiological
processes and for certain intracellular protein functions [111,112]. The average 70 kg adult male
contains approximately 100 mg of Cu, with the highest concentration distributed within the liver,
while Linder also reports an average of 1.11 µg/ml of Cu in both whole blood and in plasma [113].
Further, Cu-deficient anemia can result in skeletal deformities, and Cu deficiency is linked to
defective tissue formation [114]. Cu deficiencies also affect the metabolism of other trace
elements. For example, it increases the iron (Fe) concentration in liver significantly [115]. In
addition, Cu metabolism is affected by inflammation and infection [93]. Many studies have shown
improved angiogenesis in Cu-substituted biomaterials while no adverse effect on cellular response
was reported. Wu et al. found increased vascular endothelial growth factor (VEGF) and stabilized
hypoxia-inducible factor 1-alpha (HIF-1α) expression in Cu-doped bioglass scaffolds, whereas no
adverse effect on mesenchymal stem cell proliferation was found due to the presence of Cu [116].
Enhanced angiogenesis was also found in Cu-loaded dicalcium phosphate dihydrate (DCPD)
scaffolds at 56 and 560 ng Cu loading when implanted into the peritoneal cavity of mice [95].
Ewald et al. showed that not only the angiogenic properties but also the osteoblastic proliferation
and activity were enhanced in DCPD when loaded with 5.65 and 0.56 µg/cm2 Cu [117]. In this
work, we have focused our experiments on elucidating the effects of different concentrations of
Cu on the proliferation and differentiation of osteoblasts in ß-TCP. We investigated markers of
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differentiation and inflammation including OPG, COLA-1, ALP-1, OCN, VEGF, IL-6, TNF-
and RANKL.
We hypothesize that the addition of Cu to ß-TCP in trace amounts will alter osteoblast (OB)
cell growth and gene expression and will alter sample phase composition and microstructure. To
validate, corresponding amounts of CuO were added to TCP precursors, and samples were
prepared by uniaxial press and sintering. OB cells were seeded and allowed to grow before
harvesting and analysis by XTT and quantitative real-time polymerase reaction (qPCR). X-ray
diffraction (XRD) and scanning electron microscopy (SEM) were also utilized to analyze the phase
and microstructure of samples.

2.2
2.2.1

Materials and Methods
Sample Preparation

Pure tricalcium phosphate powder was prepared by solid-state synthesis, explained in detail
elsewhere [106]. Briefly, two moles calcium hydrogen phosphate anhydrous (CaHPO4, Alfa Aesar,
>99.0%) and one mole calcium carbonate (CaCO3, Alfa Aesar, >98.0%) were ball-milled at a
powder: milling media ratio of 1:4 for two hours and then calcined at 1050°C for 24 hours in a
muffle furnace. The calcined powder was naturally cooled to room temperature. Copper (II) oxide
was added to CaHPO4 and CaCO3 precursors at 0.25, 0.5 and 1.0 wt. % concentrations to prepare
the doped TCP, and the mixture was processed similar to undoped TCP. From now on, these
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concentrations will be referred to as Pure-TCP, 0.25 Cu-TCP, 0.5 Cu-TCP and 1.0 Cu-TCP. The
powder was then crushed and mixed with ethanol for 6 hours at a powder: ethanol ratio: milling
media ratio of 1:1.5:5. The mixture was then dried at 65 °C for 3-4 days, until all ethanol was
evaporated. Powder was poured into a 13mm diameter die set, which was held at 25.5 kN for two
minutes by a uniaxial press. Samples were then transferred to a porous zirconia substrate and
sintered at 1150°C for 2 hrs using a muffle furnace, followed by cooling to room temperature.
One issue that was discovered during the sample preparation was that the surface of all
samples was shearing off after the die was compressed with the uniaxial press. This problem was
mitigated by preparing two samples at the same time in the die. The first sample always sheared
and broke apart, but the second sample had no surface cracks or blemishes. This is because of the
length of the pin in the die set. According to the die manufacturer, the correct range of material
powder must be added to the die in order to produce desirable samples, like those in Figure 7. In
order to obtain the desired sample dimensions, the two -sample method described above was used.

Figure 7: Cu-Doped TCP Samples on Scaffolds for Sintering
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2.2.2

Phase Composition, Surface Morphology and Density

Phase composition of samples was analyzed by Rigaku D/MAX diffractometer using
CuKα radiation, equipped with Ni filter at step size of 0.04° and count time of 1.5 seconds per
step. The relative α-TCP phase intensity compared to the ß-TCP phase intensity was calculated
by:
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝛼 𝑝ℎ𝑎𝑠𝑒
Σ 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝛼 𝑎𝑛𝑑 ß 𝑝ℎ𝑎𝑠𝑒𝑠
Equation 1

After applying a thin layer coating of Pd/Au, microstructure of the top surface of samples was
performed using field emission scanning electron microscope (FESEM, Hitachi model S4500).
Relative bulk and apparent densities were measured by specimen dimension and Archimedes
method. Samples were submerged in boiling water for two minutes to ensure all trapped air was
removed from internal pores and then immediately submerged in room-temperature water to obtain
the wet weight. The relative bulk density of the samples was calculated as mass per volume of
each sample divided by the nominal density of TCP, which is 3.07 g/cm3. The percentage obtained
subtracted from 100% gave the total porosity. Apparent density was calculated as the dry weight
divided by the difference between dry and wet weight, which divided by nominal density gives
relative apparent density. This subtracted from 100% gives the percentage of closed pores, and by
subtracting this percentage from the total porosity percentage, the open porosity can be obtained.
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2.2.3

Cell Culture

The human osteoblast cell line hFOB 1.19 (referred to as hFOB), Figure 8, was purchased
from ATCC (Manassas, VA) and cultured in complete growth medium (DMEM supplemented
with 10% fetal bovine serum [FBS] and antibiotic/antimycotic). Before using, disks were sterilized
using an autoclave. Disks were placed in 24 well plates (one disk per well), and hFOB cells were
seeded on top of each disk, followed by culturing in the presence of additional cell culture media.
All experiments were conducted at 34oC in the presence of CO2.

Figure 8: Osteoblast Cells Used for Cell Culture
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2.2.4

Assessment of Cell Growth Using XTT Assay

Cells were suspended in complete growth medium at a concentration of 50 × 103 cells /20
μl. TCP disks were placed in triplicate wells of a 24-well plate. Cells (20 μl of concentrated cells)
were added to TCP disks and allowed to adhere on the top of each disk then 400 μl of complete
growth media were added to each well. Cells were cultured at 34 ºC in the presence of 5% CO 2
and media was replenished every 3-4 days. After 5 or 10 days, media were carefully removed from
wells and disks were washed gently with 1 ml DPBS (ThermoFisher Scientific, Waltham, MA).
TCP disks were then removed and placed into a new 24-well plate, followed by addition of 400 μl
of DPBS and 100 μl of XTT working solution (Trevegin, Gaithersburg, MD), and incubated at
34 ºC for 3 hours, then analyzed on an Epoch plate reader, seen in Figure 9 (Biotek, Winooski,
VT).

Figure 9: Epoch Plate Reader for XTT
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2.2.5

Assessment of Gene Expression

For gene expression studies, 2 × 106 cells in 20 μl were seeded on top of each TCP disk
in triplicate wells of 24-well plates, followed by addition of 400 μl cell culture medium. After 1
or 5 days incubation, media was removed and disks were washed gently with 1 ml DPBS.
Samples were placed into new 24-well plates and cells were immediately lysed using 1 ml
TRIzol reagent (ThermoFisher Scientific) and total RNA was isolated following manufacturer’s
protocol as previously published [109,118]. Reverse transcription reactions were performed
using Moloney murine leukemia virus (M-MLV) reverse transcriptase (Promega, Madison, WI).
Quantitative real-time PCR (qPCR) was conducted using the ViiA7 real-time PCR instrument
(Life Technologies, Grand Island, NY). Gene expression was calculated by subtracting the
threshold cycle (CT) for the housekeeping gene (GAPDH) from the gene of interest and relative
gene expression was compared to cells grown on pure TCP disks. The following primers were
used in this study: GAPDH, 5’-CTCGACTTCAACAGCGACA- 3’ (forward) and 5’GTAGCCAAATTCGTTGTCATACC-3’ (reverse); OPG, 5’GTCTTTGGTCTCCTGCTAACTC-3’ (forward) and 5’CCTCACACAGGGTAACATCTATTC-3’ (reverse); COLA1, 5’CGATGGATTCCAGTTCGAGTATG-3’ (forward) and 5’-CTTGCAGTGGTAGGTGATGTT3’ (reverse); ALP-1, 5’-CCTACCAGCTCATGCATAACA-3’ (forward) and 5’GGCTTTCTCGTCACTCTCATAC-3’ (reverse); OCN, 5’-CAGGCGCTACCTGTATCAAT-3’
(forward) and 5’-CGATGTGGTCAGCCAACT-3’ (reverse); VEGF, 5’-
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GATGAGCTTCCTACAGCACAA-3’ (forward) and 5’-CTTTCCCTTTCCTCGAACTGAT-3’
(reverse); IL-6, 5’-TCCAAAGATGTAGCCGCCC-3’ (forward) and 5’CAGTGCCTCTTTGCTGCTTTC-3’ (reverse); TNF-, 5’-CCAGGGACCTCTCTCTAATCA3’ (forward) and 5’-TCAGCTTGAGGGTTTGCTAC-3’ (reverse); and RANKL, 5’AGCACATCAGAGCAGAGAAAG-3’ (forward) and 5’-TGTCGGTGGCATTAATAGTGAG3’ (reverse).

2.2.6

Statistical Analysis

A one-way analysis of variance (ANOVA) was used to determine statistical significance
between groups. Statistical significance is denoted as * (p<0.05), ** (p<0.01), *** (p<0.001), and
**** (p<0.0001). Statistical analysis was performed by GraphPad Prism software (La Jolla, CA).
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2.3
2.3.1

Results

Phase Analysis

Relative amount of α-TCP for samples sintered at 1150 °C is listed in Table 5. Figure 10
shows XRD patterns of ß-TCP powder after calcination, initial calcination, and after sintering at
1050 °C and 1150 °C for pure-TCP, 0.25 Cu-TCP, 0.5 Cu-TCP and 1.0 Cu-TCP samples. ß-TCP
phase was the only phase present in structure of all samples after calcination and sintering at
1050 °C. Increase in sintering temperature to 1150 °C resulted in formation of α-TCP in pure-TCP,
0.25 Cu-TCP, and 0.5 Cu-TCP, whereas no secondary phase was observed in 1.0 Cu-TCP.

Table 4: α-TCP Phase Intensity Percentages

α Intensity (%)
Pure-TCP

17.46

0.25 Cu-TCP

4.92

0.5 Cu-TCP

2.76

1.0 Cu-TCP

0
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Figure 10: XRD of TCP Powder and Samples Sintered at 1050, 1150 and 1250 °C
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2.3.2

Density

The total porosity and open porosity of samples sintered at 1050 ºC and 1150 ºC were
measured and are pictured in Figure 11. In general, the porosity decreased with higher sintering
temperature at all concentrations, as seen in Table 5, except at 0.25 Cu-TCP total porosity of
1150 ºC samples was greater than 1050 ºC samples and open porosity was nearly equivalent. At
1050 ºC, among doped samples, 0.5 Cu-TCP had the greatest total and open porosity with no
difference in porosities of 0.25 Cu-TCP and 1.0 Cu-TCP.0.25 Cu-TCP had the greatest porosity at
1150 ºC, with total porosity decreasing linearly with dopant amount. The open porosity of pure
TCP was significantly less at 1150 °C and slightly less at 0.5 Cu-TCP and 1.0 Cu-TCP.

Table 5: Comparison of Open and Total Porosities at Different Sintering Temperatures

Pure TCP
0.25 Cu-TCP
0.5 Cu-TCP
1.0 Cu-TCP

1050 °C Total
Porosity
33.74 +/- 0.51
32.45 +/- 0.14
33.87 +/- 0.66
31.87 +/- 0.16
1050 °C Open
Porosity

1150 °C Total
Porosity
31.26 +/- 0.61
37.45 +/- 0.39
33.35 +/- 0.44
31.89 +/- 0.67
1150 °C Open
Porosity

%
Change
7.35%
-15.41%
1.54%
-0.06%
%
Change

Pure TCP
0.25 Cu-TCP
0.5 Cu-TCP
1.0 Cu-TCP

29.6 +/- 0.95
29.84 +/- 0.03
31.29 +/- 0.67
29.29 +/- 0.32

27.25 +/- 0.67
30.3 +/- 0.98
28.31 +/- 0.50
28.97 +/- 0.64

7.94%
-1.54%
9.52%
1.09%

36

Figure 11: Total and Open Porosity of TCP Samples Sintered at 1050 and 1150 °C

37
2.3.3

Assessment of Cell Proliferation

XTT assay was used to determine proliferation of osteoblast cells on pure and Cu-TCP
samples after 5 and 10 days of culture. OB cells were able to proliferate on pure-TCP samples as
evidenced by increased relative proliferation from day 5 to day 10 (p<0.0001) and as seen in Figure
12. We found no difference in cell proliferation between pure-TCP and 0.25 Cu-TCP samples at
both 5 and 10 days. However, the addition of higher concentrations of Cu resulted in a significant
decrease in cell proliferation at both time points in a dose-dependent manner.

Figure 12: Proliferation of Osteoblast Cells After 1 and 5 Days Incubation
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2.3.4

Assessment of Cell Differentiation and Inflammation

We evaluated inflammatory gene expression by qPCR after 1 and 5 days of sample seeding.
We found that the addition of Cu to TCP samples did not affect IL-6 expression at day 1 (Figure
13). Furthermore, although IL-6 expression increased in pure TCP samples from day 1 to day 5,
IL-6 expression was significantly reduced after 5 days for all Cu-doped samples in a dosedependent manner. Similar to IL-6, there was significant reduction in TNF- levels in Cu-doped
samples at day 1 and day 5. However, there was an increase in IL-17 expression, particularly in
samples doped with high % Cu (1%) at 1 and 5 days.
We also examined the expression of several differentiation markers in FOB grown on TCP
samples. We found that expression of osteoprotegerin (OPG) did not change in the presence of
any Cu concentration at an early time point (day 1). However, at day 5, OPG expression was
significantly reduced at 1% Cu-TCP compared to pure TCP, despite increased expression of OPG
on pure TCP samples at day 5 compared to day 1. The expression of osteocalcin (OCN) was not
affected by the presence of Cu on TCP samples at earlier and later kinetics. Similarly, the
expression of ALP-1, although initially decreased in the presence of 0.25 and 0.5% Cu on TCP, at
1% Cu, showed no difference, and at later kinetics, ALP-1 expression decreased but was not
affected by Cu. This is in contrast to vascular endothelial growth factor (VEGF), collagen type 1
alpha (COLA-1) and receptor activator of nuclear factor kappa-B ligand (RANKL), where cells
grown on 1% Cu-TCP had significantly increased expression at an early time point. However, the
presence of Cu did not alter expression at later kinetics.
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Figure 13: Gene Marker Expression of Osteoblast Cells After 1 and 5 Days Incubation
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2.4

Discussion

Calcium phosphates such as ß-TCP are a viable option for use as bone substitution materials
due to their compositional similarity to bone, as well as many other features [68,119]. Though
CaPs have limited osteoinductivity, this can be enhanced with the addition of trace elements such
as Co, Zn, Si and Cu. In this study, we synthesized ß-TCP scaffolds via the solid -state method
and sintering and studied the osteoinductivity and angiogenesis of OB cells when cultured on pure
ß-TCP scaffolds compared to Cu-doped ß-TCP. We also studied the effect of Cu addition to the
physical properties ß-TCP.
Prior to sintering all samples, two samples at each concentration were sintered at 1050°C
and 1150°C. XRD analysis was performed on each sample so that the phases present could be
identified. Samples sintered at 1150°C showed slight occurrences of α-TCP with greatest
intensities of β-TCP phases, whereas the samples sintered at 1050°C showed only occurrences of
β-TCP. Based on these findings, 1150°C was the chosen sintering temperature for the remainder
of the samples. The α-TCP transition generally occurs around 1125°C [67], which is why there are
α-TCP phases present in the 1150°C samples. The 1050°C sintering shows no presence of α-TCP,
which is expected since the α-TCP transition occurs around 1125°C.
At high sintering temperatures, trace amounts of Cu were found deposited on the inside of
the furnace that was utilized, as seen in Figure 14. This was visibly observed as pink streaks on
the heating elements, and pink dots were also noted on the pure TCP samples. The contaminated
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samples were discarded, and crucibles were utilized to cover all samples to prevent further
contamination.

Figure 14: Cu Deposition on Furnace Heating Elements

Increased levels of α-TCP result in decreased dissolution rate compared to β-TCP, which
can be seen by the solubility products and calcium to phosphate ratios of both calcium phosphates.
The solubility product of calcium phosphates increases as the Ca/P ratio decreases. However, the
calcium to phosphate ratio of both α- and β-TCP is 1.50 [120]. The solubility products of these
calcium phosphates, however, differ by a factor of 3, with α-TCP having a higher solubility product
than β-TCP [66]. Due to the increasing presence of α-TCP with increasing sintering temperature,
it can be concluded that the dissolution rate will increase with increasing sintering temperature and
that the stability of the samples therefore decreases with increasing sintering temperature. This
same trend has recently been observed in lithium-doped TCP and resulted in the decrease of
compressive strength at higher sintering temperature [84]. Because of the relatively low α-TCP
intensity compared with β-TCP found at 1150°C, this temperature was chosen as the sintering
temperature. The β- to α-TCP transition temperature has been documented as 1125°C [67], so by
sintering at 1150°C and observing the small amounts of α phase, we can be certain that 1150°C is
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a high enough temperature to complete the β-TCP reactions without having excessive occurrence
of the α phase.
Our results show that addition of Cu2+ stabilizes the β-TCP crystal structure at 1150°C,
where β-TCP to α-TCP phase transformation is expected [67]. Cu2+ incorporation decreases the
α-TCP phase in a dose-dependent manner from 17.5 in pure TCP to 4.5, 2.8 and 0 when 0.25, 0.5
and 1.0 wt% of dopant is added. Due to similar valence of Ca2+ and Cu2+, the copper ion substitutes
the Ca sites in TCP structure [121]. However, the ionic radius of Cu2+ is much smaller than Ca2+
(0.73 Å and 0.99 Å, respectively) and replacement of Ca with Cu causes the structural shrinkage,
which eventually stabilizes the β-TCP structure. This data is in accordance with previous data
where we found Ca2+ substitution with smaller Li+ and Fe3+ reduces the α-TCP occurrence
[84,122]. Studying the α-TCP formation is crucial as it increases the solubility product by a factor
of 3, so faster dissolution is expected [3].
The decrease in porosity that was observed with higher sintering temperature is expected
because at higher temperatures the particles fuse together and there is higher density as a result.
This also accounts for the decrease in open porosity for most Cu concentrations at higher
temperatures. High temperatures (around 1000-1200°C) are used to synthesize copper phosphates
from CuO, so this may also affect the density [123]. The decrease in open porosity from 1050 °C
to 1150 °C was significant for pure TCP samples but was much less so for the 0.25 Cu-TCP and
1.0 Cu-TCP samples, which suggests that Cu addition decreases the effect of increasing sintering
temperature on porosity. The same trend is apparent in total porosity as well, with the total porosity
decreasing by almost 2.5% for pure TCP but only changing by 0.5% and 0.01% for 0.5 Cu-TCP
and 1.0 Cu-TCP. Thus, it is evident that Cu addition contributes to thermal stability in this TCP.
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Copper is considered an essential trace element for humans and due to the role Cu plays in
Cu-binding proteins, Cu deficiencies have been linked to cardiomyopathy, anemia and many other
serious health issues [111,114]. On the contrary, Cu excess has been linked to cirrhosis and
decreased liver function, and excess Cu consumption has been seen to cause intestinal cramps and
nausea [114]. On a cellular level, Cu toxicity is often credited to the creation of reactive oxygen
species (ROS) by Cu ions, which ultimately leads to the breakdown of DNA strands [91].
However, in sufficiently small amounts, Cu has been reported to increase VEGF secretion in a
variety of cell types and dopant concentrations [95,116,124]. Likewise, Cu has been observed to
increase expression of osteogenic genes such as ALP, OCN and OPN, though the results of the
study by Schamel et al. show similar results between non-doped and doped samples [116,125,126].
In this study, the VEGF expression upregulated at early time points with presence of Cu in a dosedependent manner; however, at later time point, the trend did not continue. This may be due to Cu
toxicity and decreased cellular proliferation at 0.5 Cu-TCP and 1.0 Cu-TCP, resulting in fewer
cells and thus less VEGF expression. Furthermore, the increase at earlier time points may be
sufficient to induce a biological effect and sustained levels may no longer be needed. We found
that with up to 0.25 Cu-TCP, at both 5 and 10 days no significant difference in cell proliferation
could be observed compared to pure TCP. However, at 0.5 Cu-TCP, relative cellular proliferation
decreased, and at 1.0 Cu-TCP, significantly less cells were present at both time points compared
to pure TCP. This indicates that 0.25 wt. % Cu addition is near the maximum amount of Cu that
could be safely utilized as a dopant without negatively affecting cell proliferation.

Varied results were observed for osteoinductive gene expression of ALP and OCN, as there
was no difference in the expression of OCN at earlier kinetics between the four samples, but there
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was an initial decrease in ALP expression in cells grown on 0.25 Cu-TCP and 0.5 Cu-TCP and no
change at 1.0 Cu-TCP compared to pure TCP. Perhaps the lack of effect on OCN is due to its
abundance as a noncollagenous skeletal-derived protein [127] .Our study found that ALP
expression was initially higher at earlier kinetics and reduced at later kinetics (see Figure 3). This
is consistent with the expression of ALP during bone development, where it is highly expressed
during early bone development and expression is reduced later during development [128]. Both
ALP and OCN are indicators of osteoblast differentiation, and OCN is known to be produced after
maturation of the osteoblasts while ALP is an early indicator [50,129]. The observed increase in
expression of OCN at the second time point in this study corroborates this data. We found that at
early time points, increasing the dopant amount resulted in an increase of COLA-1 expression, but
at later kinetics the expression was similar for all concentrations and reduced compared to PureTCP sample at early kinetics. Since ALP is an early indicator of osteoblast differentiation and
COLA-1 is expressed prior to ALP, this trend is expected. OPG, as a decoy RANKL receptor, also
enhances differentiation, and absence of OPG has been linked to decreased bone mass in mice
[24,130].

In this study, we found that at later kinetics, OPG expression was significantly increased
with 0.25 Cu-TCP compared to pure TCP. When RANKL binds with OPG instead of RANK,
osteoclastogenesis is prevented, thus leading to enhanced bone formation [24]. IL-6 and TNF-α
are both inflammatory genes and both were downregulated with Cu dopant in this study. IL-6
promotes osteoarthritis and also leads to the upregulation of Ank, Anx-5 and Pit-1, which are all
genes that lead to calcification [40]. Likewise, increasing TNF-α leads to decreasing ALP
expression, decreasing osteoblast differentiation and upregulation of osteoclasts [46,47]. Finally,
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we found an increase in IL-17 expression at early and later kinetics. IL-17 was found to play a proosteogenic role in mesenchymal stem cells (MSCs) and therefore the induction of IL-17 expression
may play an osteogenic role [44]. Thus, we report that Cu dopants contribute to the formation of
bone and can cause therapeutic inflammation inhibition.

2.5

Conclusion

In this study are reported the effects of Cu addition to TCP scaffolds on phase composition
and physical and biological properties. Relative amounts of α-TCP phase intensity were found to
significantly decrease with increasing amounts of Cu dopant. In addition, increasing sintering
temperature was found to have less of an effect on the open porosity of samples with higher Cu
addition. Biologically, Cu dopant was found to increase osteogenic markers and decrease the
expression of proinflammatory markers.
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CHAPTER 3 COPPER- AND COBALT-DOPED BRC

3.1 Introduction

Dicalcium phosphate dihydrate (DCPD) is one type of CaP that is commonly used due to its
relatively high solubility factor of 2.5·10-7, which makes it highly resorbable. As a cement, it has
high injectability and moldability, and DCPD has increased osteoinductivity compared to other
CaPs, which leads to improved bone remodeling [66,131]. DCPD’s osteoinductivity is, however,
still relatively low, so many methods have been utilized to enhance this property, including the
incorporation of growth factors and ionic substitution [76,132]. In this study, we evaluated the
effects of doping brushite cement (BrC), a precipitate of DCPD, with Cu and Co respectively.
Copper is essential as a trace element in the body, as it helps the body handle oxidative stress
and defend against antioxidants [133]. As mentioned above, the osteoinductive properties of BrC
are limited, and methods have been explored to enhance this property. Gene markers such as
VEGF, ALP, OCN, OPG and others are good indicators of bone growth and the maximization of
their expression is desired. Growth factors can enhance these markers, as can metal dopants, which
were utilized in the present study. Co has been found to increase VEGF expression when added to
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hydroxyapatite scaffolds, and Fe increased ALP expression when added to ß-TCP [122,134]. The
physical properties of calcium phosphates are also altered by the addition of metal ions, as in the
study by Vahabzadeh et al. that showed an increase in compressive strength and density with the
addition of trace amounts of Li [84]. Another study by Bose et al. showed a significant decrease
in compressive strength with the addition of Mg, Sr and Si and showed the effects on grain size
with the addition of these dopants [110]. Cu as a dopant in various calcium phosphate biomaterials
has been well documented as integral in blood vessel formation, and angiogenesis-related gene
expression, such as vascular endothelial growth factor (VEGF), has been shown to increase with
Cu stimulation [94,135–137]. Wu et al. showed that copper-doped mesoporous bioactive glass
stimulated alkaline phosphatase (ALP), osteopontin (OPN) and osteocalcin (OCN) expression in
human bone marrow stromal cells in a dose-dependent manner [116]. In another study, ALP
activity of MC3T3-E1 mouse preosteoblast cells also increased up to 0.8 wt. % Cu addition in
silicate bioactive glass [138]. However, Li et al. directly treated human umbilical vein endothelial
cells (HUVEC) with CuSO4 and found that the expression of VEGF was not affected by Cu
stimulation [139]. Li et al. also demonstrated Cu cytotoxicity at levels above 200 μmol/L [139].
Another study showed an increase in human mesenchymal stem cell proliferation up to 0.1 mM
Cu addition to Ti-64 plates and no cytotoxicity up to 0.5 mM Cu addition [140].
Recently, cobalt (Co) has been considered for use in different CaP systems [134,141,142], Co
is present in bone, dentine, and enamel with maximum concentration of 1 ppm [65] and is part of
vitamin B12. Vitamin B12 (also known as cobalamin) plays an important role in DNA synthesis
and neurological function, and its deﬁciency is associated with hematologic disorders as well as
with neuropsychiatric disorders [143]. Reported ﬁndings show the effective role of Co2+ in
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stabilizing the hypoxia inducible factor-1α (HIF-1α) and in inducing the angiogenesis [144].
Although hypoxia (low oxygen levels, 3% O2) is important in development and wound healing,
dysregulated hypoxia plays an important role in several diseases such as cancer, heart disease, and
lung disease [145]. In fact, tumor hypoxia is one of the most common conditions encountered in
the tumor microenvironment and activates HIF-1α, which leads to the activation of a
transcriptional program that allows cells to adapt to this hypoxic environment and drives
tumorigenesis [145]. Furthermore, a role for hypoxia in promoting inﬂammatory gene expression
has been described, where it induces expression of interleukin 6 (IL-6), a cytokine that promotes
tumorigenesis [145–147]. Among the different osteosarcoma cell lines, MG-63 is a suitable
candidate to study the effects of different compositions and biomolecules on proliferation and
differentiation of malignant bone cells, in vitro [148,149]. Therefore, we have studied the effects
of Co concentration on short-term proliferation and expression of HIF-1α in the MG-63 cell line
under normoxic and hypoxic conditions.
We hypothesize that in this study the addition of Cu and Co in various concentrations to BrC
will alter the microstructure, phase composition, compressive strength, setting time, osteoblast and
MG-63 osteosarcoma cell growth (under normoxic and hypoxic conditions) and gene expression.
To validate this hypothesis, Cu and Co in appropriate amounts were added to TCP precursors and
DCPD cement samples were produced. These samples were evaluated by x-ray diffraction (XRD)
and scanning electron microscopy (SEM) to characterize the phase composition and
microstructure. Setting time was determined using a Gillmore needle, and compressive strength
was evaluated. To determine the biological impact of Cu addition, quantitative real-time
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polymerase chain reaction (qPCR) and XTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2Htetrazolium-5-carboxanilide) techniques were utilized.

3.2 Materials and Methods

3.2.1

Powder Preparation

To process the TCP powder, solid-state synthesis was used as explained elsewhere [106]. In
brief, two moles of calcium hydrogen phosphate (CaHPO4, Alfa Aesar, >98.0%) and one mole of
calcium carbonate (CaCO3, Alfa Aesar, >99.0%) were ball-milled for two hours at a powder:
milling media ratio of 1:4. The mixture was then calcined for 24 hours at 1050 °C in a muffle
furnace and cooled naturally to room temperature. The 0.25, 0.5, and 1.0 wt % copper- or cobaltdoped tricalcium phosphate was prepared by adding proper amounts of copper oxide or cobalt
oxide to the TCP precursors and then processed identically to undoped TCP (Figure 15). The
(Ca+Cu or Co)/P molar ratio was kept at 1.5 during the entire process for the different
concentrations of Cu and Co.
Following calcination, half of the TCP was kept as coarse powder and the other half was
made into fine TCP powder through mixing with ethanol and milling media for six hours at a
powder: ethanol: milling media ratio of 1:1.5:5 and then drying at 65 °C for 3-4 days.

50

Figure 15: Doped TCP Powders in Crucibles After Calcination
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3.2.2

Cement Preparation

To prepare cement powder, fine TCP, coarse TCP, and calcium phosphate monobasic
monohydrate (MCPM, Ca(H2PO4)2·H2O, Sigma-Aldrich) were mixed by mortar and pestle at a
ratio explained elsewhere [76]. Three grams of this powder was mixed consistently with 900 μL
of a polyethylene glycol (PEG, 2 wt. % in nanopure water) solution for 30 seconds and poured
into a 7mm diameter mold. The mold was covered and incubated at 37 °C and 100% humidity for
one hour. Samples were removed from the mold and kept in a phosphate-buffered saline (PBS)
solution for 24 hours to complete the setting reaction.

3.2.3

Phase Composition and Surface Morphology

X-ray diffraction was used to analyze the phase composition of samples by Rigaku D/MAX
diffractometer using CuKα radiation, step size of 0.04º, count of 1.5 seconds per step and Ni
filter. Calcined ß-TCP and brushite cement powders were analyzed, and the relative DCPD phase
intensity compared to ß-TCP phase intensity was calculated for the brushite cement by:
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𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝐷𝐶𝑃𝐷 𝑝ℎ𝑎𝑠𝑒
Σ 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝐷𝐶𝑃𝐷 𝑎𝑛𝑑 ß 𝑝ℎ𝑎𝑠𝑒𝑠
Equation 2

The surface microstructure of the samples was captured by field emission scanning electron
microscope (FESEM, Hitachi model S4500) after a thin layer of Pd/Au was applied to the top
surface.

3.2.4

Setting Time

To measure the setting time, a Gillmore needle with needles to measure initial and final setting
time was used. The cement was prepared as described above and then poured into the mold. The
0.83 inch diameter 0.25 lb. needle was used to determine the initial setting time, while the 0.042
inch diameter 1 lb. needle was used to determine the final setting time. Time was recorded from
the moment when the cement was poured into the mold until the time when the corresponding
needle ceased to indent the surface of the cement.

3.2.5

Compressive Strength

Compressive strength was measured with a 10 kN load cell. The sample was mounted in the
center of the fixture and compressed until failure was sustained. The maximum force applied was
recorded, and the compressive strength was calculated from this value and the area of the samples.
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3.2.6

Cell Culture

The human osteoblast cell line hFOB 1.19 (hFOB) was purchased from ATCC (Manassas,
VA) and maintained in complete growth medium (DMEM) supplemented with 10% fetal bovine
serum (FBS) and antibiotic/antimycotic. The MG-63 osteosarcoma cell line was purchased from
ATCC (Manassas, VA) and maintained in Eagle’s minimum essential medium (EMEM)
supplemented with 10% heat-inactivated fetal bovine serum (FBS) and antibiotic/antimycotic.
Disk samples were sterilized with 100% ethanol for 6 hours and dried under sterilized conditions
(Figure 16) prior to use. Disks were then placed in 48-well plates (one disk per well) and seeded
with hFOB cells for the Cu study and MG-63 cells for the Co study on top of each disk, followed
by addition of cell culture media. All experiments were conducted in the presence of CO2 at 34 ºC
for the hFOB and 37 °C for the MG-63.

Figure 16: Sterile Cell Culture Hood Located in Department of Biology
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3.2.7

Assessment of Cell Growth Using XTT Assay

Cells were suspended in complete growth medium at a concentration of 25 × 103 cells /20 μl.
BrC disks were placed in triplicate wells of a 48-well plate. Cells (20 μl of concentrated cells) were
added to BrC disks and allowed to adhere on the top of each disk then 400 μl of complete growth
media were added to each well. Cells were cultured at 34 ºC in the presence of 5% CO2 and media
was replenished every 3-4 days for the Cu study. For the Co study, cells were incubated under
normoxic (21% O2) or hypoxic (1% O2) conditions. After 1, 3, 5 or 7 days, media were carefully
removed from wells and disks were washed gently with 1 ml DPBS (ThermoFisher Scientific,
Waltham, MA). BrC disks were then removed and placed into a new 48-well plate followed by
addition of 400 μl of DPBS and 100 μl of XTT working solution (Trevegin, Gaithersburg, MD)
and incubated at 37 ºC for 3 hours then analyzed on an Epoch plate reader (Biotek, Winooski, VT).

3.2.8

Assessment of Gene Expression

For gene expression studies, 2 × 106 cells in 20 μl were seeded on top of each BrC disk in
triplicate wells of 48-well plates, followed by addition of 400 μl cell culture medium (
17).

Figure

For the Co study, cells were then incubated under normoxic (21% O2) or hypoxic (1% O2)
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conditions whereas all conditions were normoxic for the Cu study. After 1, 3, 5 or 7 day
incubation, media was removed and disks were washed gently with 1 ml DPBS. Samples were
placed into new 48-well plates and cells were immediately lysed using 1 ml TRIzol reagent
(ThermoFisher Scientific), and total RNA was isolated following manufacturer’s protocol as
previously published [109,118]. Reverse transcription reactions were performed using Moloney
murine leukemia virus (M-MLV) reverse transcriptase (Promega, Madison, WI). Quantitative
real-time PCR (qPCR) was conducted using the ViiA7 real-time PCR instrument (Life
Technologies, Grand Island, NY). Gene expression was calculated by subtracting the threshold
cycle (CT) for the housekeeping gene (GAPDH) from the gene of interest, and relative gene
expression was compared to cells grown on pure BrC disks. The following primers were used in
this study: GAPDH, 5’-CTCGACTTCAACAGCGACA- 3’ (forward) and 5’GTAGCCAAATTCGTTGTCATACC-3’ (reverse); OPG, 5’GTCTTTGGTCTCCTGCTAACTC-3’ (forward) and 5’CCTCACACAGGGTAACATCTATTC-3’ (reverse); COLA1, 5’CGATGGATTCCAGTTCGAGTATG-3’ (forward) and 5’-CTTGCAGTGGTAGGTGATGTT3’ (reverse); ALP-1, 5’-CCTACCAGCTCATGCATAACA-3’ (forward) and 5’GGCTTTCTCGTCACTCTCATAC-3’ (reverse); OCN, 5’-CAGGCGCTACCTGTATCAAT-3’
(forward) and 5’-CGATGTGGTCAGCCAACT-3’ (reverse); VEGF, 5’GATGAGCTTCCTACAGCACAA-3’ (forward) and 5’-CTTTCCCTTTCCTCGAACTGAT-3’
(reverse); IL-6, 5’-TCCAAAGATGTAGCCGCCC-3’ (forward) and 5’CAGTGCCTCTTTGCTGCTTTC-3’ (reverse); TNF- , 5’-CCAGGGACCTCTCTCTAATCA3’ (forward) and 5’-TCAGCTTGAGGGTTTGCTAC-3’ (reverse); and RANKL, 5’-
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AGCACATCAGAGCAGAGAAAG-3’ (forward) and 5’-TGTCGGTGGCATTAATAGTGAG3’ (reverse).
For expression of HIF-1α and glioma-associated oncogene family zinc ﬁnger 2 (GLI2)
relative to the expression of the housekeeping gene, GAPDH, the following primers were used:
b-actin, 5¢-CTCGACTTCAACAGCGACA-3¢ (forward) and 5-GTAGCCAAATTCGTTG
TCATACC-3¢ (reverse); GLI2, 5¢-CTCCGAGAAGCAAGAAGCCA-3¢ (forward) and 5GATGCTGCGGCACTCCTT-3¢ (reverse); HIF-1α, 5 ¢-AACATAAAGT
CTGCAACATGGAAG-3¢ (forward) and 5¢-TTTGATGGGTGAGGAATGGG-3¢ (reverse).

Figure 17: Brushite Cement Samples for qPCR

57
3.2.9

Statistical Analysis

A one-way analysis of variance (ANOVA) was used to determine statistical significance
between groups. Statistical significance is denoted as * (p<0.05), ** (p<0.01), *** (p<0.001),
and **** (p<0.0001). Statistical analysis was performed by GraphPad Prism software (La Jolla,
CA).

3.3 Results

3.3.1

3.3.1.1

Phase Analysis

Cu BrC Phase Analysis

The XRD data shows peaks from ß-TCP and DCPD, indicating formation of both phases
as expected. Table 6 lists the measured intensity of the 100% peaks of DCPD and ß-TCP (JCPDS
09-0077, 100% intensity at 21º, and JCPDS 09-0169, 100% intensity at 31.1º respectively).
Intensity of the DCPD phase significantly decreased with all Cu addition, with a less notable
fluctuation in ß-TCP intensity as can be seen in Figure 18 and Figure 19. Comparing ß-TCP phase
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intensity to DCPD, there is a bell curve in the doped Cu data of DCPD that is inverted for ß-TCP.
The relative DCPD phase intensity (calculated by Equation 2) also decreased with Cu dopant.

Table 6: Copper DCPD and ß-TCP Phase Intensity

Pure-BrC

0.25 Cu-BrC

0.5 Cu-BrC

1.0 Cu-BrC

DCPD Phase Intensity (a.u.)

1459

455

721

414

ß-TCP Phase Intensity (a.u.)

1605

2043

1317

2119

Relative % DCPD

47.6

18.2

35.4

16.3
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Figure 18: Copper DCPD and ß-TCP Phase Intensity
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Figure 19: Copper TCP and BrC XRD Graphs

61

3.3.1.2

Co BrC Phase Analysis

Processed TCP in the current work was used as the precursor to fabricate the BrCs. As a
result, phase analysis of TCP powders containing different concentrations of Co is necessary. XRD
spectra of different TCP powders, calcined at 1050 °C, is presented in Figure 20. The results show
that the ß-TCP (JCPDS No. 09-0169) was the only phase in pure and doped samples. No other
phase including Co was found in the TCP samples.

3.3.2

Surface Morphology

SEM microstructure of pure and Co-BrC samples shows the presence the granular TCP along
with needle/plate-like DCPD throughout the fracture surface of specimen in Figure 21 [106]. This
data is in line with the results from XRD that showed the presence of both phases in all samples.
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Figure 20: Cobalt TCP and BrC XRD Graphs
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Figure 21: Cobalt BrC SEM Images
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3.3.3

3.3.3.1

Setting Time

Cu BrC Setting Time

Figure 22 shows that increasing Cu content causes increasing setting time for both initial
and final setting times. The most significant increase in setting time can be observed between 0.5
Cu-BrC and 1.0 Cu-BrC. Initial setting time of 0.5 Cu-BrC was just over 7.5 minutes, whereas
initial setting time of 1.0 Cu-BrC was nearly double that. This is especially significant compared
to the difference between 0.25 Cu-BrC and 0.5 Cu-BrC, which was only about 1 minute, though
initial setting time of pure Cu-BrC was nearly half that of 0.25 Cu-BrC. This same general trend
can be observed in final setting times as well, with final setting time of 1.0 Cu-BrC nearly 3 times
that of 0.5 Cu-BrC. The difference between pure Cu-BrC and 0.25 Cu-BrC was slightly less
compared to initial setting time, however.

3.3.3.2

Co BrC Setting Time

The setting time of BrC doped with Co, Figure 23, increased with increasing amounts of
Co, but we observed a slight decrease in setting time between pure BrC and 0.25 Co-BrC. The
setting time of 0.5 Co-BrC and pure BrC was nearly the same for both initial and final setting
times. A significant decrease in setting time is observed between 0.5 Co-BrC and 1.0 Co-BrC for
both initial and final setting time.
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.
Figure 22: Copper BrC Initial and Final Setting Times
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Figure 23: Cobalt BrC Initial and Final Setting Times
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3.3.4

Compressive Strength

A clear bell curve can be observed in Figure 24 from the results of compressive strength testing.
The highest values of compressive strength occurred with 0.25 Cu-BrC, at which compressive
strength of 6.3 MPa was recorded, while values for pure Cu-BrC and 0.5 Cu-BrC were nearly
identical at 2.9 MPa and 3.3 MPa respectively. Addition of 1.0 Cu-BrC significantly decreased
compressive strength to 0.5 MPa.

Figure 24: Copper BrC Compressive Strength
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3.3.5

XTT Assay

To determine cell proliferation when cultured in the presence of pure, Cu-doped, and Co-doped
BrC samples, XTT assay was conducted. The relative increase in osteoblast proliferation on pure
BrC samples from day 3 to day 7 in Figure 25-A suggests that OB cells were able to proliferate.
The addition of Cu at all concentrations did decrease proliferation in a dose-dependent manner,
though cells were able to proliferate as evidenced by the increase in relative proliferation between
day 3 and day 7 for all Cu concentrations. Current results in Figure 25b show that although there
was a modest (20%) increase in MG-63 cell growth on pure BrC under hypoxia compared with
normoxia, this increase did not reach statistical signiﬁcance (Fig. 25a). Furthermore, the presence
of Co at different concentrations did not affect MG-63 cell growth on BrC under normoxic or
hypoxic conditions.

Figure 25: Relative Osteoblast and MG-63 Osteosarcoma Cell Proliferation
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3.3.6

3.3.6.1

Gene Expression

Cu-BrC Gene Expression

Gene expression by the osteoblast cells was determined by the qPCR technique, and results
can be seen in Figure 26. Cells were harvested after 1, 3 and 7-day time points and interleukin 6
(IL-6), tumor necrosis factor α (TNF-α), interleukin 17 (IL-17), osteoprotegerin (OPG), receptor
activator of nuclear factor kappa-Β ligand (RANKL), alkaline phosphatase 1 (ALP-1), vascular
endothelial growth factor (VEGF), collagen, type 1 alpha 1 (COLA-1) and osteocalcin (OCN) gene
expressions were evaluated. At early time points, IL-6, TNF-α, OPG, ALP-1 and VEGF expression
was seen to increase with increasing Cu content, but at later time points the trend was reversed.
RANKL and IL-17 expression did not occur until day 3, after which point increasing Cu amount
corresponded to increasing gene expression. OCN expression showed consistent increase with
increasing Cu for all three time points, as did COLA-1, until day 7, when all samples showed
limited expression.
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Figure 26: Gene Marker Expression of Osteoblast Cells After 1, 3 and 7 Days Incubation
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3.3.6.2

Co-BrC Gene Expression

Hypoxia is known to induce the expression of HIF-1α, so the expression of HIF-1α in thus
study was conducted under normoxic and hypoxic conditions on scaffolds with varying
concentrations of Co dopant. The expression of HIF-1α was significantly upregulated in hypoxic
conditions on pure-BrC scaffolds compared to normoxic conditions, as was GLI2 expression
(Figure 27a,b). Co dopant did not affect HIF-1α expression under normoxic conditions, though its
expression was reduced in cells cultured on 0.25 Co-BrC scaffolds (Figure 27c). Similarly, no
difference in GLI2 expression was observed with Co addition under normoxic conditions, though
1.0 Co-BrC scaffolds caused a decrease in GLI2 expression under hypoxia (Figure 27d).

3.4 Discussion

Due to its compositional similarity to bone and its properties such as injectability, brushite
cement is a feasible option for use in bone substitute applications. The limited osteoinductivity of
most CaPs such as BrC can be enhanced with the use of growth factors or, as we show in this
study, through the use of ionic substitutions. Specifically, in this study, we studied the biological
and physical effects of doping BrC scaffolds with Cu and Co. We accomplished this by
synthesizing tricalcium phosphate (TCP) powder via the solid-state method, which was then mixed
with MCPM, PEG and water to make the cement. Samples were seeded with OB or MG-63
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Figure 27: HIF-1α and GLI2 Expression Under Hypoxia and Normoxia

osteosarcoma cells that were allowed to grow on pure and doped samples to quantify the
difference in growth and gene expression with the addition of Cu or Co. Microstructure of the
samples was analyzed using XRD and SEM, and the setting time and compression strength were
also measured.
The precipitation of BrC occurs by mixing coarse and fine TCP powder with MCPM through
the following chemical reaction [150]:
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Ca3(PO4)2 + Ca(H2PO4)2 × H2O + 7H2O → 4(CaHPO4 × 2H2O)
The endothermic dissolution of MCPM, followed by the exothermic dissolution of ß-TCP,
begins the precipitation reaction, which ends with an exothermic precipitation of BrC and
increase in the system pH. All samples were prepared in the same manner, with the amount of
Cu or Co dopant the only variable.

3.4.1 Cu-BrC Discussion

The ionic radius of Cu2+ is 73 pm, while the ionic radius of Ca2+ is 99 pm. The Cu ion is
known to substitute for the Ca ion, which decreases the lattice size and increases stability. The
result of this increase in stability results in a decrease of dissolution rate and an increase in setting
time. We characterized the phases of both the TCP powder and the brushite cement to highlight
the phase change between the two. As anticipated, ß-TCP (JCPDS 09-0169) phases were present
and dominant in the TCP powder. The transition between ß-TCP to α-TCP generally occurs around
1125 °C, so the calcination of TCP at 1050 °C did not induce the α phase [67]. The impact of Cu
addition on the physical properties can clearly be seen in the XRD data of the BrC. Within the
doped samples, as the phase intensity of the DCPD increases, the phase intensity of ß-TCP
decreases and a distinct bell curve in DCPD intensity can be seen from 0.25 Cu-BrC to 1.0 CuBrC, with the peak at 0.5 Cu-BrC. The dissolution rate of DCPD is greater than that of ß-TCP by
a factor of 22, so the increase in DCPD phase intensity between 0.25 Cu-BrC and 0.5 Cu-BrC may
have contributed to the increase in setting time between the two [66]. This does not account for
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the extreme increase in setting time between 0.5 Cu-BrC and 1.0 Cu-BrC, but as discussed earlier,
the lattice shrinkage caused by the substitution of smaller Cu ions for the larger Ca ions also
contributes to the increase in setting time.
When conducting compressive strength testing, the 1.0 Cu-BrC samples were visibly
deteriorated compared to the other samples. The setting time was measured last and gave some
insight into this deterioration. As can be seen in Figure 23, the initial setting time of 1.0 Cu-BrC
was 14.67 minutes, and the final setting time was 51.17 minutes. Throughout the experiment,
samples were transferred to the 37°C environment to complete the setting time approximately 10
minutes after the cement was poured into the mold. After 1 hour, the samples were removed from
the mold and transferred to PBS to further complete setting. However, this amount of time is barely
more than the calculated final setting time of the 1.0 Cu-BrC samples. Because of this, the samples
may not have had enough time to complete the setting reactions. However, based on the trend
observed in the compression testing, one might expect the 1.0 Cu-BrC samples to have decreased
strength compared to samples with less amounts of Cu. A general increase in setting time can be
observed as the amount of Cu increases. However, there is a significant increase when 1.0 wt.
% Cu is added. This signifies that Cu addition reduces the ability of the cement to set in a timely
fashion, which is a significant consideration for injectable bone substitute materials.
Taking into account the significant increase in setting time of 1.0 Cu-BrC compared to the
other samples, the results of the compressive testing are clear. A slight decrease in strength
between 0.5 Cu-TCP and 1.0 Cu-TCP was expected, but due to the extended period of time
required to complete the setting reaction for 1.0 Cu-TCP compared to the reduced amount of time
that the samples were allowed to set, this more drastic decrease of compressive strength can also
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be expected. By observing the data, it can be postulated that the maximum compressive strength
can be obtained by adding between 0-0.5 wt. % Cu to BrC since the maximum observed
compressive strength was at 0.25 wt. % Cu. Thus, Cu has the potential to increase compressive
strength of BrC depending on dopant amount.
The importance of the presence of Cu in the body as an essential trace element has been
well documented, as has its toxicity on cellular and macro levels. Toxicity at a cellular level is
often attributed to the breakdown of DNA strands by reactive oxygen species (ROS), which are
created by Cu ions [133]. On a macro level, Cu toxicity can cause intestinal cramps, nausea and
decreased liver function [114]. In contrast, deficiency of Cu can lead to anemia and
cardiomyopathy [111,114]. Cellular studies have shown an increase in VEGF secretion by
mesenchymal stem cells with addition of Cu to bioglass scaffolds and show no toxicity up to 1 wt.
% Cu addition [135]. Wu et al. corroborate these findings and further show an increase of ALP,
OCN and OPN secretion in a dose-dependent manner, though at higher Cu concentrations cell
toxicity was observed [116]. Many other studies have indicated similar results regarding VEGF
and other osteoinductive markers, and we reported similar results previously [19–21]. In this study,
we observed osteogenic gene expression similar to our previous observations with a few notable
differences.
Herein, we observed a significant decrease in proliferation with the addition of Cu dopant
in a nearly linear dose-dependent manner at all kinetics. In our earlier study with ß-TCP scaffolds,
relative OB proliferation was nearly equal for pure and 0.25 wt. % Cu scaffolds, whereas in this
study we observed a significant decrease in relative proliferation at all concentrations of Cu. This
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highlights the difference in how cells react to various scaffolds, as all cellular procedures were
constant between experiments.
At the day 3 time point, relative proliferation of 1.0 Cu-BrC was just over 20% and at day
7 it was just under 40%. A similar trend was observed for 0.25 Cu-BrC and 0.5 Cu-BrC, which
may explain why all gene expressions except IL-17, RANKL and OCN were almost negligible at
day 7. These three genes all had relatively small gene expression at day 1, whereas at later time
points they had exponentially more expression. RANKL expression for all Cu-doped samples was
greater than 200,000% relative expression.
In a similar manner, IL-17 expression for 1.0 Cu-BrC at the latest kinetic was over
1,000,000% of relative IL-17 expression, and all doped samples were greater than 500,000%. IL17 has been linked to increased expression of ALP, but that trend was not observed in this study
[44]. Doped sample expression of ALP was increased at early time points but steadily decreased
at later kinetics. At day 7, ALP expression for all doped samples was less than that of pure BrC.
ALP is known as an early indicator of osteoblast differentiation and cellular activity, however, so
lower expression at later kinetics when proliferation was decreased can be expected [129].
IL-17 is also often associated with the production of other proinflammatory cytokines such
as IL-6 and TNF-α and has been linked to the expression of RANKL [43]. It seems that IL-17 can
enhance bone regeneration but also play a role in osteoclastogenesis and the expression of
inflammatory cytokines [43–45]. There does seem to be a link between the increase in IL-17
expression and the increase in RANKL expression at later kinetics, though there may be other
factors involved.
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The expression of IL-6 did not follow the pattern of IL-17 expression, as IL-6 expression
increased in a dose-dependent manner at the first time point, but expression slowly decreased until
at the latest kinetic almost no IL-6 expression was observed with doped samples, compared to
increased expression of IL-6 by the pure BrC at that time. IL-6 has been linked to osteoarthritis,
osteoclastogenesis and ECM mineralization and is a proinflammatory cytokine [38,39,41]. Cu may
inhibit the expression of IL-6 at later kinetics, as the increase in expression of other
osteoclastogenesis markers and proinflammatory cytokines was observed.
Similar to IL-6, TNF-α is a proinflammatory cytokine and is linked to osteoclastogenesis
and inflammatory bone diseases [46,151]. It also inhibits expression of COLA-1, OCN and reduces
the mineralization of the matrix [46,47]. TNF-α expression increased in a dose-dependent manner
at the earliest time point, after which expression decreased for all doped samples compared to pure
BrC, which suggests that at later kinetics Cu dopant had a therapeutic effect on reduction of this
inflammatory cytokine.
To regulate osteoclastogenesis, OPG acts as a decoy receptor to RANKL, which binds to
OPG instead of receptor activator of nuclear factor kappa-ß (RANK) [19,24]. This inhibits the
formation of osteoclasts and thus reduces bone resorption. Mice studies have shown that overabundance of OPG expression results in osteopetrosis, whereas osteoporosis occurs with a lack of
OPG [25]. In addition, RANKL and OPG expression have an inverse relationship, so increases in
expression of RANKL are linked to decreases in expression of OPG [19]. There is clearly such an
inverse relationship present in the data gathered in this experiment, as at later kinetics when
RANKL expression significantly increased, relative OPG expression decreased. At the first time
point, Cu-doped samples had much greater OPG expression compared to pure BrC, and the same
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trend was present to a lesser degree at the second time point. The OPG expression at the final
kinetic for all doped samples was significantly reduced compared to pure BrC at the final time
point. This suggests a trend towards favorable conditions for osteoclastogenesis because of the
increased IL-17 and RANKL expression combined with this decrease in OPG expression.
The metabolic activity of bone can be indicated by the gene OCN, the expression of which
also indicates bone formation [49]. OCN is secreted solely by osteoblasts and bonds well with the
hydroxyapatite in bone, helping to ensure mineralization [50,51]. It is secreted once the osteoblasts
are mature, which is why we see an increase in OCN expression at later kinetics. The highest levels
of OCN expressed by Cu-doped samples occurred at day 3, whereas highest expression of OCN
for the undoped samples occurred at day 7. This could indicate that osteoblast cells cultured in the
presence of Cu mature more rapidly than those cultured on pure BrC scaffolds. The increased
expression of OCN at later kinetics on doped samples compared to the pure sample suggests that
the presence of Cu does enhance osteoblast expression of OCN.
While OCN is one of the main noncollagenous proteins found in bone, collagen is by far
the most abundant protein. Combined with COLA-2, COLA-1 produces the fibril-forming type 1
collagen, which is essential to the mineralization of the bone matrix, and it is also considered a
marker of osteoblast differentiation and ALP production [48]. At early kinetics we saw a large
increase in COLA-1 production by doped samples in a dose-dependent manner, though at the final
time point all expression of COLA-1 decreased. This, combined with low expression of TNF-α at
later kinetics and high expression of OCN at early kinetics, suggests favorable bone matrix
mineralization trends with the presence of Cu.
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Angiogenesis and osteogenesis are closely related processes, and both are essential for
healthy bone growth. The vascularization of bone ensures that blood can flow and provide oxygen
to the bone. VEGF is an indicator of blood vessel growth and the ossification of bone and is mostly
expressed during mineralization [33,34,36]. Thus, the increase in expression of VEGF at early
time points for Cu-doped samples may indicate earlier mineralization compared to pure samples
and again suggest a more rapid maturation of osteoblasts cultured in the presence of Cu. Reduction
of VEGF expression at the latest kinetic for Cu-doped samples compared to pure BrC could occur
because of the later maturation of osteoblast cells cultured on the pure BrC samples.

3.4.2 Co-BrC Discussion

The Co ionic radius is 0.074 nm, and it substitutes in the Ca2+ site in CaP ceramics. As a
result of its smaller size than that of Ca2+ (0.099 nm), the substitution is accompanied by lattice
shrinkage and enhances its stability, which in turns results in a slower dissolution rate. Our XRD
results show that the ß-TCP/DCPD (JCPDS No. 09-0077) ratio (calculated from the height of
peaks with 100% intensity for ß-TCP and DCPD at 2Ɵ = 31.1° and 21°, respectively) is increasing
with the addition of dopants from 1.10 to 1.56, 1.68 and 2.02 for BrC, 0.25 Co-BrC, 0.5 Co-BrC,
and 1.0 Co-BrC, respectively [106]. These results prove that the stability of TCP decreases the
dissolution rate and, as a result, decreases the BrC formation.
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Dissolution of precursors or precipitation of DCPD resulted in a prolonged setting reaction
and in enhanced compressive strength in the Si-doped BrC system [87] and in the Cu-doped BrC
system reported earlier. In this Co-BrC system, we found that for low dopant amounts of Co, the
setting time decreased slightly, though at higher dopant amounts there was an increase in setting
time for both initial and final setting times. This most likely occurs because of the increase in ßTCP dissolution rate due to the formation of DCPD and the inhibited DCPD precipitation due to
the presence of ß-TCP.
In the present study, the Co dopants were added to TCP precursors prior to calcination. An
alternative method for adding Co dopants that was attempted was to add corresponding CoCl2 salt
dopant amounts to the PEG-H2O mixture, which was then mixed with pure powder. The samples
were formed, but while the setting reactions were completed in PBS solution, the dopant began to
leach out of the samples as seen in Figure 28. In this way, it was determined that for all samples,
dopant should be added to TCP precursors.

Figure 28: CoCl2 Leached Out of Samples

To evaluate the effects of Co and its concentration in BrC on osteosarcoma cell
proliferation, the in vitro interaction between the cells and samples was investigated under both
normoxic and hypoxic conditions. Co is a vital element in DNA synthesis, and its role as an
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antibacterial element is reported [152]. Nevertheless, high concentrations of Co can cause toxicity
in living cells [153]. Current results show that although there was a modest (20%) increase in MG63 cell growth on pure BrC under hypoxia compared with normoxia, this increase did not reach
statistical signiﬁcance. Furthermore, the presence of Co at different concentrations did not affect
MG-63 cell growth on BrC under normoxic or hypoxic conditions. These results are interesting
because a previous study found that the addition of cobalt ions directly to cell culture medium
reduced viability of osteoblasts and osteosarcoma cells in 2D culture [154]. However, the data
shown in our study represent the 3D culture condition using a scaffold. Therefore, a comprehensive
analysis of the differences between 2D and 3D cell culture models would enhance our
understanding of the effects of Co and other additives to 3D cell culture systems. On the other
hand, Zhang et al. found that addition of Co to TCP at concentrations of 2 mol.% and 5 mol.%
does not result in cytotoxicity in human bone marrow mesenchymal stem cells [142]. This proves
that although the Co shows the toxicity to some cell lines, its interaction with different cell lines
in various systems should be evaluated [142].
Because hypoxia induces the expression of HIF-1α, we examined HIF-1α expression by qPCR
in MG-63 cells cultured on Co-BrC. Consistent with previous studies [141,142], we found that
MG-63 cells cultured on pure-BrC disks under hypoxic conditions significantly upregulated the
expression of HIF-1α (p = 0.0079; Figure 27) [155]. The transcription factor GLI2 has been shown
to be induced under hypoxic conditions. Furthermore, GLI2 has been shown to be upregulated in
osteosarcoma tumor samples from patients, correlated with a poor prognosis, and its genetic
inhibition results in a reduction in cell growth and survival [156–159]. Therefore, we examined
GLI2 expression in our BrC model system. Consistent with previous studies, the expression of
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GLI2 is induced in MG-63 cells cultured under hypoxic conditions on pure BrC (p = 0.0002;
Figure 27).
We next examined the effect of Co on hypoxia-induced HIF-1α and GLI2 expression. We
found that the presence of Co ions did not affect HIF-1α expression under normoxic conditions.
Under hypoxic conditions, only the low dose of Co (0.25 wt.%) statistically reduced HIF-1α
expression. Similarly, the addition of Co had no effect on GLI2 expression under normoxia.
Nevertheless, under hypoxic conditions, the Co-BrC (1 wt.%) signiﬁcantly reduced hypoxiainduced GLI2 expression (Fig. 2e). Taken together, these data suggest that in 3D cultures using
Co-BrC, the addition of Co may reduce hypoxia-induced modulation of HIF-1α and GLI2
expression. Both hypoxia [145,160,161] and GLI2 [118,162] have been shown to induce
inﬂammatory cytokine genes. Therefore, Co may indirectly reduce inﬂammation by regulating the
expression of two proteins that regulate inﬂammation. Inﬂammation has been shown to promote
tumorigenesis [163], and it facilitates osteosarcoma cell growth [164]; therefore, this 3D Co-BrC
model system may provide therapeutic beneﬁt for osteosarcoma by reducing hypoxia-induced gene
expression.

3.5 Conclusion

In this work, the effect of Cu and Co dopants on the physical and biological characteristics of
BrC was studied. The addition of up to 0.25 wt. % Cu was found to enhance the compressive
strength of BrC samples. DCPD precipitation was clearly inhibited with the addition of Cu and
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Co, and as a result the setting time increased with increasing Cu and Co content. Cu also reduced
the expression of inflammatory markers and enhanced the expression of osteogenic markers such
as VEGF while Co inhibited the expression of proinflammatory HIF-1α and GLI2 under hypoxia.
No cytotoxicity was observed for MG-63 osteosarcoma cells under hypoxia or normoxia with
addition of Co dopant, though reduced proliferation was observed for OB cells with all amounts
of Cu dopant.
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CHAPTER 4 SUMMARY AND FUTURE WORK

4.1

Summary

Due to the prominence of diseases such as osteoporosis and arthritis, which affect people
worldwide and even in outer space, the biology, engineering, materials science and medical
communities are actively studying various biomaterials that may be utilized as bone substitute
materials. Among the materials studied are calcium phosphates, which are promising due to their
compositional similarity to bone, resorption behavior, and the ability to be used in different forms.
Calcium phosphates are naturally osteoconductive, but they lack osteoinductivity, or the ability to
induce de novo bone formation. Because of this, various methods are utilized to stimulate bone
formation in conjunction with these CaP materials, including incorporating growth factors and
trace amounts of essential elements. By integrating metal ions into the CaP materials, the physical
and mechanical properties of the material can also be modified.
In the present study, trace amounts of Cu and Co were incorporated into tricalcium phosphate
and brushite cement calcium phosphate materials in an effort to quantify the biological and
physical impact of the incorporation of these materials. An excess of these metals can also be toxic
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to the body or have an adverse effect on the physical and mechanical properties, so various trace
amounts were utilized.
As anticipated, the incorporation of Cu and Co into TCP and BrC caused changes in the
microstructure and phase diagrams of the materials. The density, setting time and compressive
strength were also altered. The compressive strength of Cu-BrC increased with 0.25 Cu dopant but
decreased with increasing amounts of Cu. The initial and final setting times of Cu and Co doped
BrC increased with increasing amounts of dopant, and a significant increase in setting time was
observed between 0.5 Cu-BrC and 1.0 Cu-BrC. Decreasing amounts of DCPD precipitation were
observed in the XRD data for BrC with incorporation of dopants. The open porosity of TCP
samples was impacted less by sintering temperature when Cu dopants were present. In addition,
the α-TCP phase was inhibited from forming by the incorporation of Cu into TCP samples.
Biologically, the incorporation of Cu and Co into samples resulted in both positive and
negative osteoinductive impacts. The expression of gene markers is commonly used to quantify
osteoinduction, and several of those markers were studied herein. In the two Cu studies, IL-17, IL6, TNF-α, RANKL, OPG, ALP-1, VEGF, COLA-1 and OCN expressions were observed. IL-17,
IL-6 and TNF-α are proinflammatory gene markers, though they have beneficial roles as well. IL17 expression increased in both studies, though IL-6 and TNF-α expression decreased at later
kinetics, suggesting that Cu plays a therapeutic role in reduction of inflammation. The early
increase in expression of ALP-1 and VEGF, and the later increase of expression in OCN indicates
that Cu plays a beneficial role in osteoinduction in osteoblasts for BrC and TCP.
The incorporation of Co into BrC samples reduced the expression of HIF-1α and GLI2 under
hypoxic conditions, which again signifies that Co has an anti-inflammatory therapeutic effect on
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MG-63 osteosarcoma cells. In addition, no cytotoxicity was observed with doped samples
compared to MG-63 proliferation on pure-BrC samples. These positive effects of Cu and Co on
the osteoinductive markers and the reduction in expression of proinflammatory markers suggest
that further investigation and laboratory testing should be conducted on these two trace elements.

4.2

Future Work

The author recommends continued research on the BrC and TCP calcium phosphates as bone
substitute materials. The compressive strength of Cu-TCP and Co-BrC were not considered in this
study, but should be investigated. In addition, therapeutic effects were observed for all dopant
amounts of Co, so increased wt. % of Co dopant may be considered. The surface morphologies
should be further considered for the Cu-doped materials as well.
Co-BrC was found to have therapeutic effects on reducing HIF-1α and GLI2 expression, but
no qPCR was conducted to quantify the effects of Co addition on other osteoinductive markers.
Further research should be conducted in considering those markers. In addition, Co-TCP was not
considered and should be investigated as a bone substitute material.
In vitro studies were conducted in the research presented herein, but further work should
include in vivo studies conducted using rabbits and rats in a laboratory setting. Histological results
offer further insight into the effects of dopants on tissue and a more complete picture of the
ramifications of utilizing potentially toxic metals. Because of the promising initial results
presented here, in vivo studies should be pursued.

87
Finally, the incorporation of other trace elements, such as Cr, should continue to be studied,
as should alternative sample fabrication methods. We have begun work to control the porosity of
TCP samples through the use of substances such as naphthalene, which can be incorporated in
controlled particle sizes and then evaporated using low-heat furnaces. The utilization of such
porous samples, and the sequential incorporation of dopants into the samples, could further
enhance the osteoinductive capacity of TCP and increase its ability to bond with bone.
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